SMILES,Name,Conditions,NCT_Number,Phases,Unapproval Probability,Approval Probability
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.2652292777440343,0.7347707222559658
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_PROGESTERONE,TRAUMATIC BRAIN INJURY,NCT04426487,Early Phase 1,0.5980266822791388,0.4019733177208612
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,URINARY TRACT INFECTIONS,NCT04301934,Not Applicable,0.12265724714405782,0.8773427528559423
CC(=O)[O-],_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.03779406949947675,0.9622059305005232
CC(=O)[O-],_ACETATE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.08277382269720843,0.9172261773027915
CC(=O)[O-],_ACETATE,DEPRESSION,NCT02837432,Early Phase 1,0.0682502899417647,0.9317497100582356
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.8193940575582903,0.18060594244170933
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,NON SMALL CELL LUNG CANCER,NCT02666105,Phase 2,0.3591957954729735,0.640804204527027
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,OVARIAN CANCER,NCT04460807,Phase 3,0.06774189361418373,0.9322581063858164
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,_FULVESTRANT,NEOPLASMS,NCT02530411,Phase 2,0.4466290520650704,0.5533709479349297
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,OVARIAN CANCER,NCT03378297,Early Phase 1,0.15291303131791256,0.8470869686820873
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.05613290463684779,0.9438670953631524
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.049062030941044235,0.950937969058956
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.0036431445395446187,0.9963568554604554
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.008643144539544617,0.9913568554604554
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,VASCULITIS,NCT03692416,Phase 3,0.002320894035024433,0.9976791059649756
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,FRONTOTEMPORAL DEMENTIA,NCT04408625,Phase 1|Phase 2,0.11843330417025145,0.8815666958297487
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.11843330417025145,0.8815666958297487
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,IDIOPATHIC MEMBRANOUS NEPHROPATHY,NCT03549663,Not Applicable,0.00014531159860123647,0.9998546884013988
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,AIRWAY INFLAMMATION,NCT03861390,Phase 1|Phase 2,0.1336461221113918,0.8663538778886084
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.186479528960626,0.8135204710393744
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.20141675325417074,0.7985832467458297
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,_ABIRATERONE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.4486321034709572,0.5513678965290428
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,_ABIRATERONE_ACETATE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.3980756034371759,0.6019243965628241
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,_FLUTAMIDE,PCOS,NCT00930228,Phase 1,0.31094601756038875,0.6890539824396116
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASMS,NCT03693612,Phase 2,0.1788784745313818,0.8211215254686182
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,SOFT TISSUE SARCOMA,NCT03449901,Phase 2,0.3431374780661838,0.6568625219338167
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,GASTRIC CANCER,NCT01924819,Phase 2|Phase 3,0.07937951536414706,0.9206204846358532
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NON-SMALL CELL LUNG CANCER METASTATIC,NCT04154956,Phase 3,0.14031419625982308,0.859685803740177
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.4538254117280578,0.5461745882719421
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,GASTRIC CANCER,NCT04178460,Phase 1,0.4147614271575001,0.5852385728425001
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PROSTATE CANCER,NCT04194554,Phase 1|Phase 2,0.5605300815052427,0.4394699184947571
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,BREAST CANCER,NCT02826512,Phase 2,0.3527937874454028,0.6472062125545974
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PANCREATIC CANCER,NCT03601923,Phase 2,0.5548285638471131,0.4451714361528868
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,OVARIAN NEOPLASMS,NCT03955471,Phase 2,0.6130476755993285,0.3869523244006712
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,METASTATIC MELANOMA,NCT03925350,Phase 2,0.5548285638471131,0.4451714361528868
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACYCLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.1262411108898423,0.8737588891101578
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACICLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.1262411108898423,0.8737588891101578
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.33729955670654044,0.6627004432934597
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,OVARIAN CANCER,NCT03464201,Phase 2,0.4609773259188356,0.5390226740811644
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,BREAST CANCER,NCT02955394,Phase 2,0.4492371127069056,0.5507628872930944
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.16636589191359152,0.8336341080864089
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,NEOPLASMS,NCT03967223,Phase 2,0.13080996769167086,0.8691900323083293
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.006285775655884828,0.9937142243441152
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PROSTATE CANCER,NCT03089203,Phase 1,0.14861345936207382,0.8513865406379266
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PANCREATIC CANCER,NCT04390399,Phase 2,0.16077727746644982,0.8392227225335506
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,GRAFT VS HOST DISEASE,NCT03357159,Phase 2,0.07554581012271913,0.9244541898772809
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,METASTATIC RENAL CELL CARCINOMA,NCT02926053,Phase 1,0.07554581012271913,0.9244541898772809
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,METASTATIC MELANOMA,NCT03475134,Phase 1,0.07554581012271913,0.9244541898772809
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,EPIDERMOLYSIS BULLOSA,NCT01033552,Phase 2,0.2854779834756306,0.7145220165243696
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,RHABDOMYOSARCOMA,NCT04388839,Phase 2,0.1193079715488434,0.8806920284511569
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.2854779834756306,0.7145220165243696
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,HEPATOCELLULAR CARCINOMA,NCT04011033,Phase 2|Phase 3,0.0021510725819990713,0.9978489274180008
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,RETINOBLASTOMA,NCT02870907,Phase 2,0.00424581067933721,0.9957541893206628
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OSTEOSARCOMA,NCT03063983,Phase 2,0.013680158008694742,0.9863198419913054
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.2854779834756306,0.7145220165243696
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,MULTIPLE SCLEROSIS,NCT03477500,Phase 3,0.004891050717064611,0.9951089492829354
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,DIFFUSE LARGE B CELL LYMPHOMA,NCT04214626,Phase 2,0.030017496655352787,0.9699825033446474
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,VASCULITIS,NCT03692416,Phase 3,0.0038147489979119226,0.996185251002088
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,BREAST CANCER,NCT02897700,Phase 1,0.0012129889287788695,0.9987870110712213
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.02922963582593595,0.9707703641740644
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,UVEITIS|MACULAR EDEMA,NCT02623426,Phase 3,0.1941854254325341,0.8058145745674659
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.2665227201467147,0.7334772798532857
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,OSTEOSARCOMA,NCT03063983,Phase 2,0.005155303710206666,0.9948446962897934
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,PERIPHERAL T CELL LYMPHOMA,NCT03321890,Phase 2,0.030017496655352787,0.9699825033446474
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,PROLIFERATIVE VITREORETINOPATHY,NCT04482543,Phase 2|Phase 3,0.004788257966419662,0.9952117420335804
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,IDIOPATHIC MEMBRANOUS NEPHROPATHY,NCT03549663,Not Applicable,0.0032569113660270675,0.996743088633973
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,EPIDERMOLYSIS BULLOSA,NCT02582775,Phase 2,0.1426244978639316,0.8573755021360685
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.24147313147405536,0.7585268685259448
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,ACUTE MYELOID LEUKEMIA,NCT03467386,Phase 1,0.2951357558700664,0.7048642441299335
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,SEVERE APLASTIC ANEMIA,NCT02918292,Phase 2,0.3017983790014538,0.6982016209985463
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,LYMPHEDEMA,NCT04390685,Phase 1|Phase 2,0.022972414840859767,0.9770275851591402
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,LYMPHOMA,NCT03151876,Phase 2,0.16494928432379874,0.8350507156762014
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,EPIDERMOLYSIS BULLOSA,NCT02582775,Phase 2,0.1925378062654067,0.8074621937345932
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.32676938372163244,0.6732306162783676
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.18829628330993006,0.8117037166900701
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,NEOPLASMS,NCT03967223,Phase 2,0.17911621227985858,0.8208837877201418
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,GRAFT VS HOST DISEASE,NCT03263767,Phase 2,0.04281729095859181,0.9571827090414082
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,METASTATIC RENAL CELL CARCINOMA,NCT02926053,Phase 1,0.05160922133854154,0.9483907786614586
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,METASTATIC MELANOMA,NCT03475134,Phase 1,0.05160922133854154,0.9483907786614586
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,EPIDERMOLYSIS BULLOSA,NCT01033552,Phase 2,0.4044674850659222,0.5955325149340779
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.4044674850659222,0.5955325149340779
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,HEPATOCELLULAR CARCINOMA,NCT02905188,Phase 1,0.4072396961067765,0.5927603038932237
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,PERIPHERAL T CELL LYMPHOMA,NCT04083495,Phase 2,0.4072396961067765,0.5927603038932237
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,GASTRIC CANCER,NCT01924819,Phase 2|Phase 3,0.15624571735450435,0.8437542826454957
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,GLIOBLASTOMA,NCT02669173,Phase 1,0.43732138678334737,0.5626786132166526
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,HEPATOCELLULAR CARCINOMA,NCT04411706,Phase 2,0.1556826869588986,0.8443173130411012
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,STOMACH NEOPLASMS,NCT03675737,Phase 3,0.2856210803681506,0.7143789196318495
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,COLORECTAL CANCER METASTATIC,NCT04245865,Phase 2,0.15624571735450435,0.8437542826454957
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,HEAD AND NECK NEOPLASMS,NCT03678649,Phase 2,0.13618593196034426,0.8638140680396559
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,OVARIAN CANCER,NCT03936270,Phase 2,0.6673032318413809,0.33269676815861915
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.3073416176106311,0.6926583823893689
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,PROSTATE CANCER,NCT02905318,Phase 2,0.7080728829364632,0.2919271170635365
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,_ANASTROZOLE,PULMONARY ARTERIAL HYPERTENSION,NCT03229499,Phase 2,0.6561414381079099,0.3438585618920898
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,SOFT TISSUE SARCOMA,NCT03114527,Phase 2,0.1838808948862473,0.8161191051137529
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,"CARCINOMA, RENAL CELL",NCT04195750,Phase 3,0.02708264917087354,0.9729173508291266
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,END STAGE RENAL DISEASE,NCT03413722,,0.23764586990696124,0.7623541300930391
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,_RIBOCICLIB,SOFT TISSUE SARCOMA,NCT03114527,Phase 2,0.5898337291823011,0.4101662708176986
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,_RIBOCICLIB,EARLY BREAST CANCER,NCT03701334,Phase 3,0.6168592186059996,0.3831407813940004
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,MULTIPLE MYELOMA,NCT03442673,Phase 2,0.1938818915516452,0.8061181084483551
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.3263497117300391,0.6736502882699611
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,RHABDOMYOSARCOMA,NCT04299113,Phase 1,0.5040078763625635,0.4959921236374365
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,LUNG ADENOCARCINOMA,NCT03891173,Phase 2,0.3465305073386682,0.653469492661332
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.05756929577291842,0.9424307042270816
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,SOFT TISSUE SARCOMA,NCT03449901,Phase 2,0.3316818614699728,0.6683181385300275
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,MULTIPLE MYELOMA,NCT03442673,Phase 2,0.05675964264126901,0.9432403573587312
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04182204,Phase 3,0.114221743024983,0.8857782569750172
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,NK/T CELL LYMPHOMA,NCT04230330,Phase 1,0.16510984336197995,0.8348901566380204
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,METASTATIC BREAST CANCER,NCT03901339,Phase 3,0.114221743024983,0.8857782569750172
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,ADVANCED PANCREATIC CANCER,NCT04098081,Phase 2,0.2095958018929855,0.7904041981070148
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NON SMALL CELL LUNG CANCER,NCT02477826,Phase 3,0.20519814925750576,0.7948018507424944
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASMS,NCT03693612,Phase 2,0.19335020013630988,0.8066497998636903
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,GASTRIC CANCER,NCT03801668,Phase 3,0.09382188436100013,0.906178115639
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,PANCREATIC CANCER,NCT04054362,Phase 2,0.09099327481494188,0.9090067251850584
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,SMALL CELL LUNG CANCER,NCT04210037,Phase 1|Phase 2,0.143160150659779,0.8568398493402211
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,GASTROINTESTINAL STROMAL TUMORS,NCT03944304,Phase 2,0.07093822547949166,0.9290617745205084
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,_EPIRUBICIN,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.02576787245592382,0.9742321275440762
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,_EPIRUBICIN,GASTRIC CANCER,NCT01924819,Phase 2|Phase 3,0.06172317194441378,0.9382768280555862
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.44246782098794346,0.557532179012057
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,NON SMALL CELL LUNG CANCER,NCT03334617,Phase 2,0.4052537190187478,0.5947462809812525
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,OVARIAN CANCER,NCT03378297,Early Phase 1,0.3043938697136107,0.6956061302863897
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.27965246957112144,0.7203475304288787
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER,NCT03810105,Phase 2,0.6127956372096657,0.3872043627903341
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PULMONARY ARTERIAL HYPERTENSION,NCT03782818,Phase 1|Phase 2,0.4096445917652412,0.5903554082347591
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,COLORECTAL CANCER,NCT04166435,Phase 2,0.6369183402603587,0.36308165973964096
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER METASTATIC,NCT03434158,Phase 2,0.3440275395657257,0.6559724604342745
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,MYELODYSPLASTIC SYNDROME,NCT02936752,Phase 1,0.96835836251951,0.03164163748049008
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,ACUTE MYELOID LEUKEMIA,NCT01305499,Phase 2,0.4779379308693878,0.5220620691306124
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,NEUROENDOCRINE TUMORS,NCT03211988,Phase 2,0.8204280694213142,0.17957193057868598
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,_MITOXANTRONE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.14500115598111318,0.8549988440188869
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_VASOPRESSIN,HYPERTENSION,NCT04170751,Not Applicable,0.1695652758277324,0.8304347241722678
N=C(N)NCCC[C@H](N)C(=O)O,_ARGININE,SOFT TISSUE SARCOMA,NCT03449901,Phase 2,0.4977638678761115,0.5022361321238885
N=C(N)NCCC[C@H](N)C(=O)O,_ARGININE,GASTRIC CANCER,NCT01704664,Not Applicable,0.1593588990979846,0.8406411009020154
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,NON SMALL CELL LUNG CANCER,NCT03661567,Phase 2,0.0014787683597988954,0.9985212316402012
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,FRONTOTEMPORAL DEMENTIA,NCT04408625,Phase 1|Phase 2,0.17247102169125875,0.8275289783087415
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.17247102169125875,0.8275289783087415
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PNEUMONIA,NCT03852537,Phase 2,0.04999459700477513,0.9500054029952251
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.25900486226495495,0.7409951377350451
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.17247102169125875,0.8275289783087415
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,COVID-19 PNEUMONIA,NCT04438980,Phase 3,0.0016331241646257914,0.9983668758353744
NC[C@H](O)c1ccc(O)c(O)c1,_NOREPINEPHRINE,HYPERTENSION,NCT04170751,Not Applicable,0.06598642549574364,0.9340135745042568
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,PANCREATIC CANCER,NCT04048278,Early Phase 1,0.006767763096300114,0.9932322369036996
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,POMPE DISEASE,NCT02240407,Phase 1,0.04931222476457342,0.9506877752354268
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,CHRONIC LOW BACK PAIN,NCT03046017,Not Applicable,0.006317872659348914,0.9936821273406509
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,"PAIN, CHRONIC",NCT02983682,Phase 3,0.20174476155654925,0.7982552384434509
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,CONTRACEPTION,NCT02799641,Not Applicable,0.022534966740650208,0.9774650332593499
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,METASTATIC MELANOMA,NCT03817125,Phase 1,0.04008379450755045,0.9599162054924496
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,ULCERATIVE COLITIS,NCT03759041,Phase 2,0.05140297765782217,0.9485970223421779
CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,_TEICOPLANIN,BACTERIAL INFECTIONS,NCT03933748,,0.3919120801476945,0.6080879198523057
CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,_TEICOPLANIN,CYSTIC FIBROSIS,NCT04176328,Phase 1,0.5608014530300791,0.4391985469699207
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,_AMIKACIN,PNEUMONIA VENTILATOR ASSOCIATED,NCT03149640,Phase 3,0.08562350656949212,0.914376493430508
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,_LINEZOLID,TUBERCULOUS MENINGITIS,NCT03898635,,0.2645814031450356,0.7354185968549645
Nc1nc(=O)c2ncn(COCCO)c2[nH]1,_ACYCLOVIR,UVEITIS,NCT03389191,Not Applicable,0.2492787036245395,0.7507212963754606
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,_GENTAMICIN,ABDOMINAL ABSCESS,NCT03476941,Phase 2,0.15166642869369298,0.8483335713063073
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,_GANCICLOVIR,TRANSPLANTATION INFECTION|CYTOMEGALOVIRUS INFECTIONS,NCT03699254,Phase 3,0.03777355964008895,0.9622264403599112
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,_CYCLOSPORINE,EPIDERMOLYSIS BULLOSA,NCT01033552,Phase 2,0.25145502278059384,0.7485449772194065
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,EPIDERMOLYSIS BULLOSA,NCT01033552,Phase 2,0.4668994548323866,0.5331005451676133
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.4668994548323866,0.5331005451676133
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,ACUTE MYELOID LEUKEMIA,NCT02782546,Phase 2,0.3656593134959352,0.6343406865040649
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SEVERE APLASTIC ANEMIA,NCT02918292,Phase 2,0.5748169620683912,0.4251830379316088
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,BREAST CANCER,NCT01646034,Phase 3,0.16025434137767228,0.8397456586223278
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.2627819772437551,0.7372180227562453
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,RETINOBLASTOMA,NCT02870907,Phase 2,0.16010384355489254,0.8398961564451076
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.5051649032733994,0.4948350967266005
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,FRONTOTEMPORAL DEMENTIA,NCT04408625,Phase 1|Phase 2,0.21613010812191127,0.7838698918780892
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.21613010812191127,0.7838698918780892
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.2129971416181108,0.7870028583818892
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,SEVERE APLASTIC ANEMIA,NCT02979873,Phase 2,0.18375284046823925,0.8162471595317611
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,BETA-THALASSEMIA,NCT03877809,Phase 2,0.012960763670183595,0.9870392363298164
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,DRY EYE,NCT04115800,Early Phase 1,0.00439102653481712,0.9956089734651828
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,_CLADRIBINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03318419,Phase 2,0.2235558558597543,0.7764441441402459
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,_CLADRIBINE,LYMPHOMA,NCT03151876,Phase 2,0.16838764573004422,0.8316123542699558
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,_CYTARABINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.3823992818397404,0.6176007181602601
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,_CYTARABINE,MYELODYSPLASTIC SYNDROME,NCT03412266,Phase 2,0.04035695635979735,0.9596430436402028
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,_ELTROMBOPAG,ACUTE MYELOID LEUKEMIA,NCT03603795,Phase 2,0.1695404327456578,0.8304595672543426
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,_ELTROMBOPAG,SEVERE APLASTIC ANEMIA,NCT04304820,Phase 2,0.5821224025332087,0.4178775974667913
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.12288795364070085,0.8771120463592994
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.5745782642790883,0.4254217357209117
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,METASTATIC MELANOMA,NCT01920516,,0.3011755434507091,0.698824456549291
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.4037891511737703,0.5962108488262297
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.5200531681505037,0.4799468318494964
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,ACUTE MYELOID LEUKEMIA,NCT02771197,Phase 2,0.5745782642790883,0.4254217357209117
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,_VEDOTIN,NON SMALL CELL LUNG CANCER,NCT03539536,Phase 2,0.26107672202005416,0.7389232779799464
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,_VEDOTIN,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04182204,Phase 3,0.6001752830275122,0.3998247169724877
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,_VINCRISTINE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.12735669325754986,0.8726433067424503
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,_VINCRISTINE,RHABDOMYOSARCOMA,NCT04388839,Phase 2,0.30606114353935715,0.6939388564606429
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,_LEUCOVORIN,GASTRIC CANCER,NCT01924819,Phase 2|Phase 3,0.1378214351414941,0.8621785648585061
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,_LEUCOVORIN,PANCREATIC CANCER,NCT04390399,Phase 2,0.203879488550514,0.7961205114494864
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,_LEUCOVORIN,COLORECTAL CANCER METASTATIC,NCT03164655,Phase 2,0.1378214351414941,0.8621785648585061
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,DEPRESSION,NCT02837432,Early Phase 1,0.1153404625523658,0.8846595374476343
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,PROSTATE CANCER,NCT00859781,Phase 2,0.2019228424332287,0.7980771575667716
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,SEPSIS,NCT04160676,Not Applicable,0.016834400092819026,0.983165599907181
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,HIV INFECTION,NCT03237689,Early Phase 1,0.2449258340353822,0.7550741659646178
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,_ETOPOSIDE,NON SMALL CELL LUNG CANCER,NCT03840902,Phase 2,0.17643873855647713,0.8235612614435229
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,_ETOPOSIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.31300941177552644,0.6869905882244737
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,_ETOPOSIDE,OSTEOSARCOMA,NCT04154189,Phase 2,0.20059056774000664,0.7994094322599934
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,PROSTATIC NEOPLASMS,NCT04034095,,0.050844086864518766,0.9491559131354812
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,ASTHMA IN CHILDREN,NCT03962894,,0.17695595622742186,0.8230440437725782
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.0009895776601548324,0.9990104223398452
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,_IDARUBICIN,HEPATOCELLULAR CARCINOMA,NCT04178642,Phase 2,0.07759263728170743,0.9224073627182928
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,_IDARUBICIN,"CARCINOMA, HEPATOCELLULAR",NCT03727633,Phase 2,0.1802140373990084,0.8197859626009918
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,_IDARUBICIN,ACUTE MYELOBLASTIC LEUKEMIA,NCT01296178,Not Applicable,0.024112405337609773,0.9758875946623904
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,_AZATHIOPRINE,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.23978480789555195,0.7602151921044482
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER,NCT03513211,Phase 1|Phase 2,0.0618006766384718,0.9381993233615284
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE MYELOMA,NCT04163107,Phase 1,0.12336420928501166,0.8766357907149884
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.2851190007464575,0.7148809992535425
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,TYPE 1 DIABETES,NCT03428945,Phase 2,0.06510597566217217,0.934894024337828
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,POMPE DISEASE,NCT02240407,Phase 1,0.08248351482294489,0.9175164851770552
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.4354195113613277,0.5645804886386724
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.04363134949976985,0.9563686505002302
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.11899104251134307,0.8810089574886572
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,ANALGESIA,NCT03955211,Phase 2,0.3465389158060588,0.6534610841939414
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,POMPE DISEASE,NCT02240407,Phase 1,0.15242514782797809,0.847574852172022
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.39403569922790976,0.6059643007720898
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.1139393186922836,0.8860606813077168
CNNCc1ccc(C(=O)NC(C)C)cc1,_PROCARBAZINE,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT03495960,Phase 2,0.22519139785857334,0.7748086021414268
O=P1(NCCCl)OCCCN1CCCl,_IFOSFAMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03736616,Phase 2,0.2535167721114245,0.7464832278885758
O=P1(NCCCl)OCCCN1CCCl,_IFOSFAMIDE,OSTEOSARCOMA,NCT04154189,Phase 2,0.23494649154656574,0.7650535084534346
O=C(O)[C@H](O)[C@@H](O)C(=O)O,_TARTRATE,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT03450629,Phase 3,0.2908279453258007,0.7091720546741993
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,_SELUMETINIB,NON SMALL CELL LUNG CANCER,NCT03392246,Phase 2,0.8521213571351541,0.14787864286484595
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,_SELUMETINIB,NEUROFIBROMATOSIS TYPE 1,NCT04495127,Phase 1,0.8672034612191355,0.13279653878086464
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,_OCTREOTIDE,GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR,NCT03972488,Phase 3,0.16023445532798153,0.8397655446720185
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.0034365051291121327,0.996563494870888
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,UVEITIS|MACULAR EDEMA,NCT02623426,Phase 3,0.09871646876302036,0.9012835312369798
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.019651091433813384,0.9803489085661868
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,NK/T CELL LYMPHOMA,NCT04230330,Phase 1,0.044902554811567984,0.955097445188432
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,LYMPHOMA,NCT02436707,Phase 2,0.003787671356364065,0.996212328643636
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,GRAFT VS HOST DISEASE,NCT00391170,Phase 2,0.06013653548975428,0.9398634645102456
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,WALDENSTRÖM MACROGLOBULINEMIA,NCT04463953,Phase 2,0.019651091433813384,0.9803489085661868
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,CUSHING DISEASE,NCT03974789,,0.1403374120550959,0.8596625879449041
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,_TOLVAPTAN,"POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT",NCT02847624,,0.2855649941869699,0.71443500581303
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,_DEXTROSE,OSTEO ARTHRITIS OF THE KNEES,NCT03400631,Not Applicable,0.11300063044384312,0.8869993695561572
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,_SULFASALAZINE,PRIMARY SCLEROSING CHOLANGITIS,NCT03561584,Phase 2,0.2749084827475996,0.7250915172524007
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,_SOMATOSTATIN,HEPATOCELLULAR CARCINOMA,NCT02799212,Phase 3,0.08464178269086027,0.9153582173091398
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,_CABERGOLINE,ENDOMETRIOSIS,NCT03928288,Phase 2,0.2381863801857273,0.7618136198142728
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,GASTRIC CANCER,NCT04005365,Phase 2,0.16965670214081907,0.8303432978591812
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,PORTAL HYPERTENSION,NCT03094234,Not Applicable,0.03325365684541847,0.9667463431545816
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,POSTPARTUM HAEMORRHAGE,NCT03434444,Not Applicable,0.122732957978894,0.8772670420211061
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,OBSTRUCTIVE SLEEP APNEA,NCT03049306,Phase 2,0.20280154589550173,0.7971984541044986
Clc1cccc(Cl)c1NC1=NCCN1,_CLONIDINE,CRITICAL ILLNESS,NCT03653832,Phase 3,0.0767101936093413,0.9232898063906588
CC(=O)Nc1nnc(S(N)(=O)=O)s1,_ACETAZOLAMIDE,SMALL CELL LUNG CANCER,NCT03467360,Phase 1,0.4101027036479431,0.589897296352057
CC(=O)Nc1nnc(S(N)(=O)=O)s1,_ACETAZOLAMIDE,"HYPOXIA, ALTITUDE",NCT04251364,Not Applicable,0.039289888100724174,0.960710111899276
CC(=O)Nc1nnc(S(N)(=O)=O)s1,_ACETAZOLAMIDE,"HYPERTENSION, PULMONARY",NCT02755298,Phase 2|Phase 3,0.060417795704498185,0.9395822042955018
CC12CC3CC(C)(C1)CC(N)(C3)C2,_MEMANTINE,SICKLE CELL DISEASE,NCT03247218,Phase 2,0.1598234959553347,0.8401765040446655
CC12CC3CC(C)(C1)CC(N)(C3)C2,_MEMANTINE,COGNITION DISORDERS,NCT03342443,Phase 2|Phase 3,0.012345638902846907,0.9876543610971532
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MULTIPLE SCLEROSIS,NCT04035889,Not Applicable,0.11118341500866484,0.8888165849913353
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,POSTOPERATIVE DELIRIUM,NCT04483596,,0.15976991665685708,0.840230083343143
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,OBSTRUCTIVE SLEEP APNEA,NCT02484300,Not Applicable,0.269159160568936,0.7308408394310643
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,IRRITABLE BOWEL SYNDROME,NCT04193501,Phase 3,0.04825632190821641,0.9517436780917836
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,OSTEOPENIA,NCT04233112,Early Phase 1,0.23806066618059865,0.7619393338194017
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MIGRAINE DISORDERS,NCT03597529,Phase 2,0.12210324641583988,0.8778967535841603
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,_SERTRALINE,MYELODYSPLASTIC SYNDROME,NCT02452983,Phase 1,0.4475433103539419,0.5524566896460584
N[C@@H](Cc1c[nH]cn1)C(=O)O,_HISTIDINE,"RENAL INSUFFICIENCY, CHRONIC",NCT02947750,Phase 2,0.5221096035483668,0.477890396451633
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,"RENAL INSUFFICIENCY, CHRONIC",NCT02947750,Phase 2,0.2419750884572288,0.7580249115427715
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,DELIRIUM,NCT04456985,Not Applicable,0.045642183553961914,0.9543578164460382
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,ANEMIA,NCT04404751,Not Applicable,0.05734787639361112,0.9426521236063892
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,AMYOTROPHIC LATERAL SCLEROSIS,NCT03427086,Phase 2,0.2649098004253816,0.7350901995746186
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,ANEMIA,NCT02757898,Phase 1,0.616243896401331,0.38375610359866896
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,SICKLE CELL DISEASE|SICKLE CELL ANEMIA,NCT04476277,Early Phase 1,0.6898819414947844,0.3101180585052155
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,_AZITHROMYCIN,BACTERIAL INFECTIONS,NCT03925480,Phase 3,0.0049284240797555275,0.9950715759202444
c1ccc([C@H]2CN3CCSC3=N2)cc1,_LEVAMISOLE,APLASTIC ANEMIA,NCT03218657,Not Applicable,0.11607082731966775,0.8839291726803323
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,_ANLOTINIB,OVARIAN CANCER,NCT03924882,Phase 2,0.2651459279772612,0.7348540720227389
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,_ANLOTINIB,SOFT TISSUE SARCOMA,NCT03890068,Phase 2,0.3386934602803912,0.6613065397196091
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,_ANLOTINIB,GLIOBLASTOMA,NCT04119674,Phase 1|Phase 2,0.2325329759359665,0.7674670240640339
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,_ANLOTINIB,HEPATOCELLULAR CARCINOMA,NCT03945799,Phase 1|Phase 2,0.2325329759359665,0.7674670240640339
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,_ANLOTINIB,GASTROINTESTINAL STROMAL TUMORS,NCT04106024,Phase 2,0.3746835534313034,0.6253164465686968
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,_ANLOTINIB,THYROID CANCER,NCT04309136,Phase 2,0.24207515657419806,0.7579248434258021
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,_ANLOTINIB,"CARCINOMA, HEPATOCELLULAR",NCT04066543,Phase 2,0.2743200919027196,0.7256799080972806
NC(=O)CC[C@H](N)C(=O)O,_GLUTAMINE,GASTRIC CANCER,NCT01704664,Not Applicable,0.7256081076367562,0.2743918923632437
NC(=O)CC[C@H](N)C(=O)O,_L-GLUTAMINE,GASTRIC CANCER,NCT01704664,Not Applicable,0.7256081076367562,0.2743918923632437
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,_PERINDOPRIL,ALZHEIMER DISEASE,NCT02085265,Phase 2,0.04239048203031626,0.9576095179696836
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,SEPSIS,NCT04160676,Not Applicable,0.050565873273055235,0.9494341267269448
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,GLIOBLASTOMA MULTIFORME,NCT02344355,Phase 2,0.6254126472641748,0.3745873527358252
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,SEPSIS,NCT04160676,Not Applicable,0.097281165578032,0.902718834421968
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,DELIRIUM,NCT04214106,,0.2428114568329821,0.7571885431670181
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,_AZACITIDINE,PANCREATIC CANCER,NCT01845805,Phase 2,0.3772401845419248,0.6227598154580751
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,_AZACITIDINE,PERIPHERAL T CELL LYMPHOMA,NCT04480125,Phase 2,0.3821788438185644,0.6178211561814361
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,_PAZOPANIB,GLIOBLASTOMA MULTIFORME,NCT02331498,Phase 1|Phase 2,0.3892185756570557,0.6107814243429442
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,_PAZOPANIB,KIDNEY CANCER,NCT03571438,Not Applicable,0.1990543838367756,0.8009456161632245
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,SMALL CELL LUNG CANCER,NCT04400188,Phase 1|Phase 2,0.15818070978233156,0.8418192902176684
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,COLORECTAL CANCER,NCT04166435,Phase 2,0.44746495374182543,0.5525350462581745
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,GLIOMA,NCT03257618,Not Applicable,0.20010234303503555,0.7998976569649647
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,GLIOBLASTOMA MULTIFORME,NCT02344355,Phase 2,0.4630904286657919,0.5369095713342082
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT03495960,Phase 2,0.061581498469410224,0.9384185015305899
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT04214626,Phase 2,0.20195666360845355,0.7980433363915467
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,MANTLE CELL LYMPHOMA,NCT04109872,,0.20892693388144412,0.7910730661185559
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04404283,Phase 3,0.2332305139706373,0.7667694860293628
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,NON HODGKIN LYMPHOMA,NCT02180711,Phase 1|Phase 2,0.3473911355701219,0.6526088644298785
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,_POMALIDOMIDE,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,NCT04191616,Phase 2,0.8474556760393521,0.1525443239606477
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,BREAST CANCER,NCT02790580,Phase 2,0.10338610162934077,0.8966138983706595
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,OSTEOSARCOMA,NCT03900793,Phase 1,0.4541117597424053,0.5458882402575946
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,STOMACH NEOPLASMS,NCT03170180,Phase 2,0.10420854293888017,0.8957914570611202
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,GASTROINTESTINAL STROMAL TUMORS,NCT03673501,Phase 3,0.28727056234089904,0.7127294376591015
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,KIDNEY CANCER,NCT03571438,Not Applicable,0.05858275041392544,0.9414172495860746
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,RENAL CELL CARCINOMA,NCT02919371,Phase 1|Phase 2,0.07732251736810666,0.9226774826318934
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,PANCREATIC NEUROENDOCRINE TUMORS,NCT02282059,,0.1220469989633116,0.8779530010366886
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_TEMSIROLIMUS,KIDNEY CANCER,NCT03571438,Not Applicable,0.207988775931826,0.7920112240681741
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,_FLUDEOXYGLUCOSE,GLIOBLASTOMA,NCT04315584,Early Phase 1,0.9944017022668196,0.005598297733180277
N[C@@H](Cc1ccc(O)cc1)C(=O)O,_TYROSINE,THYROID CANCER,NCT04521348,Phase 2,0.5273529676990417,0.4726470323009583
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.5150621486856891,0.4849378513143108
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,LYMPHOMA,NCT02974647,Phase 2,0.4393272618887527,0.5606727381112474
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,CORONAVIRUS INFECTION,NCT04348695,Phase 2,0.329065714321047,0.6709342856789536
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,MALARIA,NCT04456634,Phase 1,0.21483811412666395,0.7851618858733365
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,HODGKIN LYMPHOMA,NCT03681561,Phase 1|Phase 2,0.6287069956214613,0.3712930043785385
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,GASTRIC CANCER,NCT04358341,Phase 2,0.012082545546826608,0.9879174544531736
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,RETINOBLASTOMA,NCT01783535,Phase 2,0.21431688284036696,0.7856831171596329
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,METASTATIC BREAST CANCER,NCT04159818,Phase 2,0.10819557412553972,0.8918044258744605
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,OVARIAN CANCER,NCT04337632,Phase 3,0.1827288309071069,0.8172711690928933
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,MANTLE CELL LYMPHOMA,NCT03710772,Phase 2,0.6011851885809133,0.3988148114190864
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,_BRIGATINIB,NON SMALL CELL LUNG CANCER,NCT04074993,Phase 2,0.6535573227132576,0.34644267728674216
COC(=O)C(c1ccccc1)C1CCCCN1,_METHYLPHENIDATE,ANXIETY,NCT02153944,Not Applicable,0.07012078565299616,0.929879214347004
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,LIVER CIRRHOSIS,NCT02642874,Phase 3,0.04840484864666551,0.9515951513533346
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,OSTEOPOROSIS,NCT04550078,Not Applicable,0.07339824744790388,0.9266017525520964
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,_LUTEIN,PROSTATE CANCER,NCT04136353,Phase 3,0.3938400865128541,0.6061599134871459
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,_LUTEIN,GLAUCOMA,NCT03959592,Phase 1|Phase 2,0.5687816061829607,0.43121839381703936
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,PROSTATE CANCER,NCT03769766,Phase 3,0.1898251259678886,0.8101748740321116
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,BREAST CANCER,NCT03980509,Phase 1,0.6554742902588728,0.3445257097411272
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,ULCERATIVE COLITIS,NCT02277223,Phase 3,0.1089584459033222,0.8910415540966778
NCC(=O)O,_GLYCINE,MILD COGNITIVE IMPAIRMENT,NCT03493178,Early Phase 1,0.5125081489756541,0.4874918510243459
CC(=O)N[C@@H](CS)C(=O)O,_ACETYLCYSTEINE,MILD COGNITIVE IMPAIRMENT,NCT03493178,Early Phase 1,0.263738560549874,0.7362614394501266
CC(=O)N[C@@H](CS)C(=O)O,_ACETYLCYSTEINE,IDIOPATHIC PULMONARY FIBROSIS,NCT04312594,Phase 2,0.3134081672468169,0.6865918327531834
CN(CC(=O)O)C(=N)N,_CREATINE,INTERMITTENT CLAUDICATION,NCT02993874,Not Applicable,0.35137641462431396,0.6486235853756859
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,HIV INFECTION,NCT04425902,Phase 1,0.34467761781812983,0.6553223821818702
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,CROHN'S DISEASE,NCT03358706,Phase 1,0.22125053145499465,0.7787494685450055
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,CATARACT,NCT03534973,Not Applicable,0.04739633290046253,0.9526036670995373
CC(C)C[C@H](N)C(=O)O,_LEUCINE,DEPRESSION,NCT03557684,Early Phase 1,0.509250422692313,0.490749577307687
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,_VITAMIN_E,BREAST CANCER,NCT04463459,Not Applicable,0.034295934759564856,0.9657040652404352
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04011930,Phase 2,0.049830253351139935,0.9501697466488602
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,END STAGE RENAL DISEASE,NCT04145492,Phase 2|Phase 3,0.039434627584565236,0.9605653724154348
CN(C)C(=N)NC(=N)N,_METFORMIN,NON SMALL CELL LUNG CANCER,NCT03874000,Phase 2,0.28491476166875523,0.7150852383312448
CN(C)C(=N)NC(=N)N,_METFORMIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.12772892039715153,0.8722710796028486
CN(C)C(=N)NC(=N)N,_METFORMIN,BREAST CANCER,NCT04559308,Phase 2,0.0072848734424330675,0.992715126557567
CN(C)C(=N)NC(=N)N,_METFORMIN,FAMILIAL ADENOMATOUS POLYPOSIS,NCT01725490,Phase 2,0.012119457985133673,0.9878805420148664
CN(C)C(=N)NC(=N)N,_METFORMIN,GLIOBLASTOMA,NCT03151772,Early Phase 1,0.09225193567763754,0.9077480643223624
CN(C)C(=N)NC(=N)N,_METFORMIN,FRAGILE X SYNDROME,NCT04141163,Phase 1|Phase 2,0.04110932993623631,0.9588906700637638
CN(C)C(=N)NC(=N)N,_METFORMIN,GLIOBLASTOMA MULTIFORME,NCT02780024,Phase 2,0.33801125270697824,0.6619887472930219
CN(C)C(=N)NC(=N)N,_METFORMIN,PRIMARY OPEN ANGLE GLAUCOMA,NCT04155164,Not Applicable,0.0037895136098096303,0.9962104863901904
CN(C)C(=N)NC(=N)N,_METFORMIN,HEART FAILURE,NCT03331861,Phase 2,0.049537537907645916,0.950462462092354
CN(C)C(=N)NC(=N)N,_METFORMIN,"RENAL INSUFFICIENCY, CHRONIC",NCT02895750,Phase 2,0.09225193567763754,0.9077480643223624
CN(C)C(=N)NC(=N)N,_METFORMIN,PREECLAMPSIA,NCT03717701,Not Applicable,0.010553244836658452,0.9894467551633416
CN(C)C(=N)NC(=N)N,_METFORMIN,RHEUMATOID ARTHRITIS,NCT04068246,Early Phase 1,0.00507104840316906,0.9949289515968308
CN(C)C(=N)NC(=N)N,_METFORMIN,ABDOMINAL AORTIC ANEURYSM,NCT03507413,Phase 2|Phase 3,0.04816964439832063,0.9518303556016796
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,NEOPLASMS,NCT02964013,Phase 1,0.21450114633414785,0.7854988536658523
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,NON-SMALL CELL LUNG CANCER METASTATIC,NCT04163432,Phase 2,0.22503971258146765,0.7749602874185326
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,COLORECTAL CANCER,NCT02588781,Phase 2,0.15468341273420444,0.8453165872657956
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,NON-SQUAMOUS NSCLC,NCT03802240,Phase 3,0.15264073491800473,0.8473592650819954
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,CARCINOMA|NON-SMALL-CELL LUNG,NCT03952403,Phase 3,0.15264073491800473,0.8473592650819954
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.09002852992167723,0.909971470078323
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,COLORECTAL CANCER,NCT03957902,Phase 2,0.0137064725685374,0.9862935274314628
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,SEPSIS,NCT01784159,Phase 2,0.0030051224177062865,0.9969948775822935
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.13573325117385054,0.8642667488261496
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,AORTIC STENOSIS,NCT03557242,Not Applicable,0.02805586465548606,0.9719441353445141
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,CRITICAL ILLNESS,NCT02285751,Phase 2,0.0030051224177062865,0.9969948775822935
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT04160546,Phase 2,0.18215875700814724,0.8178412429918527
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,LIVER TRANSPLANT; COMPLICATIONS,NCT04327427,,0.22035322328618054,0.7796467767138197
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,OVARIAN CANCER,NCT03378297,Early Phase 1,0.09002852992167723,0.909971470078323
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,COLORECTAL CANCER,NCT03957902,Phase 2,0.0137064725685374,0.9862935274314628
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,SEPSIS,NCT01784159,Phase 2,0.0030051224177062865,0.9969948775822935
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.13573325117385054,0.8642667488261496
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,AORTIC STENOSIS,NCT03557242,Not Applicable,0.02805586465548606,0.9719441353445141
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,CRITICAL ILLNESS,NCT02285751,Phase 2,0.0030051224177062865,0.9969948775822935
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT04160546,Phase 2,0.18215875700814724,0.8178412429918527
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,LIVER TRANSPLANT; COMPLICATIONS,NCT04327427,,0.22035322328618054,0.7796467767138197
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,_MORPHINE,NEUROPATHIC PAIN,NCT01914042,Phase 2,0.005121903288300933,0.9948780967116992
NC(N)=O,_UREA,HELICOBACTER PYLORI INFECTION,NCT04233684,Not Applicable,0.33618060870296423,0.6638193912970359
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,_ICOSAPENT_ETHYL,ALZHEIMER DISEASE,NCT02719327,Phase 2|Phase 3,0.4520163920439227,0.5479836079560774
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,_VITAMIN_A,EFFICACY AND SAFETY,NCT03779776,Not Applicable,0.11468096308792265,0.8853190369120776
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,SCHIZOPHRENIA,NCT04094207,Phase 1|Phase 2,0.12982580295559676,0.8701741970444031
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT02451774,Phase 2|Phase 3,0.13762543795176652,0.8623745620482335
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,BREAST CANCER,NCT02958852,Phase 2,0.01953023042352772,0.9804697695764724
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,COLORECTAL CANCER,NCT04151355,Not Applicable,0.008338793037451756,0.9916612069625482
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,"HYPOXIA, ALTITUDE",NCT04251364,Not Applicable,0.013598890318841695,0.9864011096811584
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,RHEUMATOID ARTHRITIS,NCT03770702,Phase 3,0.12034496429063213,0.8796550357093682
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,OBESITY,NCT03777215,Early Phase 1,0.3211591414625734,0.6788408585374267
NNC(=O)c1ccncc1,_ISONIAZID,TUBERCULOUS MENINGITIS,NCT03787940,Not Applicable,0.08157334616009719,0.9184266538399031
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,_DARUNAVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.5644599014776813,0.4355400985223188
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,_DOLUTEGRAVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.6564451447038354,0.3435548552961646
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,MULTIPLE SCLEROSIS,NCT03161028,Phase 2,0.26135247636882,0.7386475236311801
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,AMYOTROPHIC LATERAL SCLEROSIS,NCT04518540,Not Applicable,0.0592183023599694,0.9407816976400306
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,_FRUCTOSE,CHRONIC KIDNEY DISEASE,NCT01407627,Not Applicable,0.14763593881764378,0.8523640611823563
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,_FRUCTOSE,NONALCOHOLIC FATTY LIVER DISEASE,NCT01930123,Phase 2,0.3937900932721212,0.6062099067278787
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,_FRUCTOSE,ACUTE KIDNEY INJURY,NCT04310514,Not Applicable,0.1352768149690562,0.8647231850309438
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,GASTRIC CANCER,NCT04379596,Phase 2,0.2119678546284216,0.7880321453715784
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,BREAST CANCER,NCT02897700,Phase 1,0.13473724411572174,0.8652627558842785
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,COLORECTAL CANCER METASTATIC,NCT04245865,Phase 2,0.13387070386837455,0.8661292961316258
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,_IRINOTECAN,GASTRIC CANCER,NCT04358341,Phase 2,0.09510823077906123,0.9048917692209392
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,_IRINOTECAN,PANCREATIC CANCER,NCT04390399,Phase 2,0.2608805929945058,0.7391194070054944
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,_IRINOTECAN,COLORECTAL CANCER METASTATIC,NCT03164655,Phase 2,0.1226224045624825,0.8773775954375179
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,_IRINOTECAN_HYDROCHLORIDE,SMALL CELL LUNG CANCER,NCT04381910,Phase 2,0.45868772479200104,0.5413122752079991
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,HIV INFECTION,NCT04425902,Phase 1,0.433954862095979,0.5660451379040211
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,PREECLAMPSIA,NCT03648970,Phase 2,0.05040948785642331,0.9495905121435768
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,NCT04284657,Phase 2,0.06495793160075268,0.9350420683992476
COCCc1ccc(OCC(O)CNC(C)C)cc1,_METOPROLOL,HIV INFECTION,NCT04425902,Phase 1,0.3715636175906256,0.6284363824093745
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,DYSPEPSIA,NCT02621359,Phase 3,0.08674220063267471,0.9132577993673257
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,HIV INFECTION,NCT04425902,Phase 1,0.3002076803339827,0.6997923196660174
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,CROHN'S DISEASE,NCT03358706,Phase 1,0.18047487122542336,0.8195251287745766
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,_DIGOXIN,HIV INFECTION,NCT04425902,Phase 1,0.6301878829239338,0.3698121170760664
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.03339627178848767,0.9666037282115124
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,HIV INFECTION,NCT04425902,Phase 1,0.4211645327872146,0.5788354672127854
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.03339627178848767,0.9666037282115124
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,ALZHEIMER DISEASE,NCT03991988,Phase 2,0.11485378749013796,0.8851462125098623
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,PAIN,NCT02793375,Phase 3,0.09950311661341338,0.9004968833865868
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,BREAST CANCER,NCT04172220,Not Applicable,0.014383539536903113,0.9856164604630968
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,HIV INFECTION,NCT04425902,Phase 1,0.3616586304444697,0.6383413695555302
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,CROHN'S DISEASE,NCT03358706,Phase 1,0.2671568323588051,0.7328431676411953
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,"HEPATITIS B, CHRONIC",NCT02952924,Phase 1,0.12574944954062708,0.8742505504593732
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,FATIGUE,NCT04141696,Phase 1|Phase 2,0.13758680557848535,0.8624131944215148
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,_ROSUVASTATIN,OVARIAN CANCER,NCT03532139,Phase 2,0.3125727650205099,0.6874272349794903
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_LOVASTATIN,FRAGILE X SYNDROME,NCT02998151,Phase 2,0.3029189094810009,0.6970810905189994
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_SIMVASTATIN,LYMPHOMA,NCT04514029,Early Phase 1,0.4549786773393933,0.5450213226606069
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_SIMVASTATIN,CORONAVIRUS INFECTION,NCT04348695,Phase 2,0.16358990257669384,0.8364100974233062
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_SIMVASTATIN,DILATED CARDIOMYOPATHY,NCT03775070,Phase 2,0.24648543618602586,0.7535145638139744
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,_SACUBITRIL,HYPERTROPHIC CARDIOMYOPATHY,NCT03832660,Phase 2,0.21053495283618384,0.7894650471638165
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,MYOCARDIAL INFARCTION,NCT03715998,Phase 2,0.11436284123797474,0.8856371587620255
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,MILD COGNITIVE IMPAIRMENT,NCT02646982,Phase 2,0.26489401687564146,0.7351059831243586
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,PERIPHERAL NEUROPATHY,NCT03688633,Phase 2,0.12725663099990006,0.8727433690001001
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,_TELMISARTAN,ALZHEIMER DISEASE,NCT02085265,Phase 2,0.06884460818427901,0.9311553918157212
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_IRBESARTAN,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,NCT03493685,Phase 3,0.20768772590964496,0.7923122740903554
CN1CCC[C@H]1c1cccnc1,_NICOTINE,MILD COGNITIVE IMPAIRMENT,NCT02720445,Phase 2,0.13541944169759626,0.8645805583024039
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,_BUPROPION,WILSON DISEASE,NCT04526210,Phase 1,0.18723806224589112,0.8127619377541091
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,CLUSTER HEADACHE,NCT02981173,Phase 1,0.5865897221920612,0.41341027780793865
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,NICOTINE DEPENDENCE,NCT01943994,Not Applicable,0.677146747102695,0.3228532528973052
[C-]#[O+],_CARBON_MONOXIDE,ACUTE RESPIRATORY DISTRESS SYNDROME,NCT03799874,Phase 2,0.6329304159368472,0.3670695840631527
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,_BUPROPION_HYDROCHLORIDE,WILSON DISEASE,NCT04526210,Phase 1,0.4425509613751506,0.5574490386248494
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,_HALOPERIDOL,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.2555056530608516,0.7444943469391485
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,BREAST CANCER,NCT03109990,Not Applicable,0.020266827112070455,0.9797331728879294
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,INFECTIVE ENDOCARDITIS,NCT02698930,Not Applicable,0.012319319605067838,0.9876806803949322
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,CRITICAL ILLNESS,NCT03653832,Phase 3,0.03472420625084749,0.9652757937491524
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,ALZHEIMER DISEASE,NCT04205539,Phase 1,0.3904729052117341,0.6095270947882659
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,ANALGESIA,NCT04442906,Not Applicable,0.012319319605067838,0.9876806803949322
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,PHEOCHROMOCYTOMA,NCT04320589,Phase 2,0.01616817441415262,0.9838318255858474
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,KIDNEY TRANSPLANTATION,NCT03327389,Not Applicable,0.012319319605067838,0.9876806803949322
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,POSTOPERATIVE DELIRIUM,NCT03120442,Not Applicable,0.0177991772864889,0.9822008227135112
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03129828,Phase 1|Phase 2,0.17140183108445525,0.828598168915545
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,ACUTE MYELOID LEUKEMIA,NCT04173585,Phase 2,0.08787278089284402,0.912127219107156
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,_CLOFARABINE,GRAFT VS HOST DISEASE,NCT03263767,Phase 2,0.8459642321843229,0.15403576781567693
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,_VALGANCICLOVIR,GLIOBLASTOMA MULTIFORME,NCT04116411,Phase 2,0.07615482712054714,0.923845172879453
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,_VALGANCICLOVIR,TRANSPLANTATION INFECTION|CYTOMEGALOVIRUS INFECTIONS,NCT03699254,Phase 3,0.07615482712054714,0.923845172879453
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,_SORAFENIB,"CARCINOMA, HEPATOCELLULAR",NCT02794337,Phase 2|Phase 3,0.22419764177017776,0.7758023582298221
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,_CELECOXIB,ANALGESIA,NCT03974932,Phase 3,0.5731168691300038,0.4268831308699961
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,_CELECOXIB,WILSON DISEASE,NCT04526197,Phase 1,0.25976206619479625,0.7402379338052039
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,_IMATINIB,COVID-19 PNEUMONIA,NCT04346147,Phase 2,0.0534745728302236,0.9465254271697764
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,_IMATINIB,STOMACH NEOPLASMS,NCT03170180,Phase 2,0.12177020881709574,0.8782297911829043
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,_IMATINIB,PLASMODIUM FALCIPARUM MALARIA (DRUG RESISTANT),NCT03697668,Phase 2,0.1579810701237394,0.8420189298762611
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,PANCREATIC CANCER,NCT03563248,Phase 2,0.1136101120073296,0.8863898879926704
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,OSTEOSARCOMA,NCT03900793,Phase 1,0.3867909426488095,0.6132090573511906
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ACUTE MYELOID LEUKEMIA,NCT02013648,Phase 3,0.22238109059991854,0.7776189094000814
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ALZHEIMER DISEASE,NCT04063124,Phase 1|Phase 2,0.345569341489507,0.6544306585104933
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,"MYELOID LEUKEMIA, CHRONIC",NCT02890784,Phase 3,0.22238109059991854,0.7776189094000814
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,CHRONIC KIDNEY DISEASE,NCT02848131,Phase 2,0.2777145842563027,0.7222854157436974
O=C(CCCCCCC(=O)Nc1ccccc1)NO,_VORINOSTAT,CROHN'S DISEASE,NCT03167437,Phase 1|Phase 2,0.9716511697070424,0.028348830292957726
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,_COBIMETINIB,NON SMALL CELL LUNG CANCER,NCT03178552,Phase 2|Phase 3,0.7660598742470596,0.2339401257529401
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,_COBIMETINIB,METASTATIC MELANOMA,NCT04109456,Phase 1,0.8790568649192536,0.12094313508074644
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,_PANOBINOSTAT,HIV INFECTION,NCT02471430,Phase 1|Phase 2,0.4709962271118374,0.5290037728881625
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,_CABOZANTINIB,NON SMALL CELL LUNG CANCER,NCT04131543,Phase 2,0.4167294891475861,0.5832705108524138
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,_CABOZANTINIB,METASTATIC RENAL CELL CARCINOMA,NCT03149822,Phase 1|Phase 2,0.5217826182504942,0.4782173817495057
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,_CABOZANTINIB,"CARCINOMA, RENAL CELL",NCT04338269,Phase 3,0.4065451183330592,0.5934548816669409
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,_VEMURAFENIB,NON SMALL CELL LUNG CANCER,NCT03178552,Phase 2|Phase 3,0.6449820288584317,0.3550179711415681
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,_REGORAFENIB,GASTRIC CANCER,NCT03627728,Phase 2,0.3196196110370947,0.6803803889629058
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,_REGORAFENIB,THYROID CANCER,NCT02657551,Phase 2,0.7855545344387042,0.21444546556129584
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,_REGORAFENIB,"CARCINOMA, HEPATOCELLULAR",NCT03347292,Phase 1,0.5411700341225518,0.4588299658774482
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,_PONATINIB,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT04160546,Phase 2,0.7889455852102643,0.2110544147897354
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,NON SMALL CELL LUNG CANCER,NCT03087448,Phase 1|Phase 2,0.6691997373948108,0.3308002626051889
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.3433183841054448,0.6566816158945552
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,MULTIPLE MYELOMA,NCT03091257,Phase 1,0.6474660801653749,0.35253391983462506
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,METASTATIC MELANOMA,NCT02392871,Phase 1|Phase 2,0.42460923465900907,0.575390765340991
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,MENINGIOMA,NCT03631953,Phase 1,0.42460923465900907,0.575390765340991
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,_DABRAFENIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.2964314750412883,0.7035685249587118
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,_DABRAFENIB,MULTIPLE MYELOMA,NCT03091257,Phase 1,0.5103507807890244,0.4896492192109755
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,_DABRAFENIB,METASTATIC MELANOMA,NCT02392871,Phase 1|Phase 2,0.3461479073575129,0.6538520926424874
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,_IDELALISIB,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03742323,Phase 1|Phase 2,0.6842173036600314,0.31578269633996825
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,NON SMALL CELL LUNG CANCER,NCT03829332,Phase 3,0.773980451623994,0.22601954837600605
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,BREAST CANCER,NCT03168074,Phase 2,0.8772201027504428,0.1227798972495569
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,OSTEOSARCOMA,NCT04154189,Phase 2,0.746250631951506,0.2537493680484939
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,BREAST CANCER,NCT04298918,Phase 1|Phase 2,0.9602156795854966,0.03978432041450357
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,MANTLE CELL LYMPHOMA,NCT03523975,Phase 1,0.9807563043743645,0.019243695625635517
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,SMALL CELL LUNG CANCER,NCT04422210,Phase 1,0.9663448251259064,0.03365517487409357
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,MYELODYSPLASTIC SYNDROME,NCT02942290,Phase 1,0.9096625582886072,0.0903374417113928
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,_ABEMACICLIB,PROSTATE CANCER,NCT03706365,Phase 2,0.6449425016454671,0.3550574983545329
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,_ABEMACICLIB,BREAST CANCER,NCT04565054,Phase 3,0.6022766030221094,0.39772339697789066
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,_ABEMACICLIB,GLIOBLASTOMA,NCT02977780,Phase 2,0.6776649909429204,0.3223350090570792
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,_LORLATINIB,NON SMALL CELL LUNG CANCER,NCT02927340,Phase 2,0.498296895771333,0.5017031042286668
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,_LORLATINIB,ADVANCED CANCERS,NCT03726333,Phase 1,0.5130008921979179,0.4869991078020821
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,_COPANLISIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT04263584,Phase 2,0.8437965604524013,0.15620343954759866
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,NON SMALL CELL LUNG CANCER,NCT03874000,Phase 2,0.5107605281364516,0.4892394718635486
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,BREAST CANCER,NCT04170465,Phase 2,0.185995397208862,0.8140046027911383
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,HEART FAILURE,NCT03331861,Phase 2,0.3717852833142002,0.6282147166857999
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.27023967845181435,0.7297603215481859
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,MANTLE CELL LYMPHOMA,NCT03891355,Phase 2,0.2559500810962007,0.7440499189037995
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,MULTIPLE MYELOMA,NCT03989414,Phase 1|Phase 2,0.2938966414374604,0.7061033585625396
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,_CLARITHROMYCIN,PARKINSON'S DISEASE,NCT03440112,Phase 1|Phase 2,0.2053153665873966,0.7946846334126033
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,_IXAZOMIB,MANTLE CELL LYMPHOMA,NCT03616782,Phase 2,0.35631009814697395,0.6436899018530261
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,_SELINEXOR,NON SMALL CELL LUNG CANCER,NCT03095612,Phase 1|Phase 2,0.9765566813857516,0.023443318614248164
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,_SELINEXOR,GLIOBLASTOMA MULTIFORME,NCT04421378,Phase 1|Phase 2,0.7835800112137211,0.21641998878627888
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,_SELINEXOR,CORONAVIRUS INFECTION,NCT04349098,Phase 2,0.8197586558387873,0.18024134416121265
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,_THALIDOMIDE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.15951513473286702,0.8404848652671331
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,_THALIDOMIDE,THALASSEMIA,NCT03651102,Phase 2|Phase 3,0.16453238170325699,0.8354676182967432
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,_VINDESINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.18390452590245224,0.8160954740975478
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03129828,Phase 1|Phase 2,0.17285221465083275,0.8271477853491673
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,PROSTATE CANCER,NCT02643667,Phase 1|Phase 2,0.4710083355906077,0.5289916644093923
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,LYMPHOMA,NCT02436707,Phase 2,0.32674410752806216,0.6732558924719378
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,GRAFT VS HOST DISEASE,NCT04235036,Phase 2,0.44327146015838986,0.5567285398416102
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,GLIOBLASTOMA,NCT03535350,Phase 1,0.3872302475144213,0.6127697524855787
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,NON-HODGKIN'S LYMPHOMA,NCT03198026,Phase 2,0.44327146015838986,0.5567285398416102
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,_DUVELISIB,PERIPHERAL T CELL LYMPHOMA,NCT03372057,Phase 2,0.9384738091590228,0.061526190840977074
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,METASTATIC RENAL CELL CARCINOMA,NCT04049344,Phase 2,0.1306728274662942,0.869327172533706
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,HODGKIN LYMPHOMA,NCT03250962,Phase 2,0.041730359731281336,0.9582696402687191
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,NON HODGKIN LYMPHOMA,NCT04337606,Phase 1|Phase 2,0.09133405593503087,0.9086659440649693
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02753062,Phase 2,0.3259190153672077,0.6740809846327923
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,MULTIPLE MYELOMA,NCT04083898,Phase 1|Phase 2,0.4452639790619304,0.5547360209380695
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02763319,Phase 2|Phase 3,0.1900543410427088,0.8099456589572914
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,PERIPHERAL T CELL LYMPHOMA,NCT04083495,Phase 2,0.4990336746986607,0.5009663253013393
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.013400579962998396,0.9865994200370016
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,"LYMPHOMA, T-CELL, CUTANEOUS",NCT03116659,Early Phase 1,0.4306599227077016,0.5693400772922984
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,INFERTILITY,NCT03824340,Not Applicable,0.022392110460121063,0.977607889539879
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,_CARBIDOPA,AGE-RELATED MACULAR DEGENERATION,NCT03023059,Phase 2,0.4752854975695391,0.524714502430461
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,_TOPIRAMATE,SCHIZOPHRENIA,NCT02808533,Not Applicable,0.08673942967762238,0.9132605703223776
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,PCOS,NCT04213677,Phase 3,0.12291792902179748,0.8770820709782028
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.19281097211817064,0.8071890278818296
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,ALZHEIMER DISEASE,NCT03801642,Phase 1|Phase 2,0.19281097211817064,0.8071890278818296
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,NONALCOHOLIC STEATOHEPATITIS,NCT03723252,Phase 3,0.10193001088636536,0.8980699891136349
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,AGING,NCT04401904,Phase 1|Phase 2,0.19281097211817064,0.8071890278818296
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,_EXENATIDE,PARKINSON'S DISEASE,NCT04305002,Phase 2,0.06841122754865771,0.9315887724513424
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,_DICLOFENAC,BREAST CANCER,NCT04511832,Not Applicable,0.13899461805462762,0.8610053819453727
CC(C)Cc1ccc(C(C)C(=O)O)cc1,_IBUPROFEN,VASCULITIS,NCT03692416,Phase 3,0.0004966238637665722,0.9995033761362332
CC(C)Cc1ccc(C(C)C(=O)O)cc1,_IBUPROFEN,ANALGESIA,NCT03955211,Phase 2,0.3099752819671051,0.690024718032895
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,_FLUCONAZOLE,CRYPTOCOCCAL MENINGITIS,NCT03945448,Phase 2|Phase 3,0.1252893981843018,0.8747106018156983
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,_POSACONAZOLE,INVASIVE ASPERGILLOSIS,NCT04218851,Phase 2,0.19978825310110698,0.8002117468988931
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,_TRIMETHOPRIM,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.5169095807353505,0.4830904192646495
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,_CASPOFUNGIN,FUNGAL INFECTION,NCT03857399,Phase 2,0.10821256664443928,0.8917874333555609
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,_VORICONAZOLE,INVASIVE PULMONARY ASPERGILLOSIS,NCT03672292,Phase 2,0.19662232740022265,0.8033776725997774
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,_CIPROFLOXACIN,PNEUMONIA,NCT03177720,Phase 1,0.0031012516650121237,0.9968987483349878
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,_RITONAVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.4410488866983555,0.5589511133016445
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,_CLOBETASOL_PROPIONATE,CATARACT,NCT04249076,Phase 3,0.28924198653752103,0.7107580134624791
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,_CLOBETASOL,CATARACT,NCT04249076,Phase 3,0.15399760939132126,0.8460023906086788
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,INFECTION,NCT03844776,Not Applicable,0.10732670020163386,0.8926732997983663
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,PERIODONTITIS,NCT03733379,Phase 3,0.019060847965599943,0.9809391520344
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,_DEXTROMETHORPHAN,CROHN'S DISEASE,NCT03358706,Phase 1,0.3358864856376058,0.6641135143623944
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,_DEXTROMETHORPHAN,AMYOTROPHIC LATERAL SCLEROSIS,NCT03883581,Phase 1|Phase 2,0.4491728507662989,0.5508271492337011
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,_BINIMETINIB,NON SMALL CELL LUNG CANCER,NCT03915951,Phase 2,0.7476758130429316,0.25232418695706843
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,_BINIMETINIB,PANCREATIC CANCER,NCT03637491,Phase 2,0.6110737373076996,0.3889262626923001
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,_WARFARIN,PANCREATIC CANCER,NCT03536208,Early Phase 1,0.63612227584509,0.36387772415490977
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,_WARFARIN,CROHN'S DISEASE,NCT03358706,Phase 1,0.30957775497316925,0.6904222450268307
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,_WARFARIN,AORTIC STENOSIS,NCT03557242,Not Applicable,0.15156162116953908,0.8484383788304612
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,TRAUMATIC BRAIN INJURY,NCT04058132,Phase 2,0.16410325726073902,0.8358967427392611
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,PREECLAMPSIA,NCT03724838,Not Applicable,0.029049268974875968,0.9709507310251241
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,CYSTIC FIBROSIS,NCT04039087,Phase 2|Phase 3,0.04441197690008596,0.955588023099914
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,GLAUCOMA,NCT04052269,Phase 3,0.09524653102384424,0.904753468976156
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,BIRTH ASPHYXIA,NCT04169191,Phase 1,0.07445034377021365,0.9255496562297864
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,BRONCHOPULMONARY DYSPLASIA,NCT03142568,Phase 2,0.06564040575159523,0.9343595942484048
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,TRAUMATIC BRAIN INJURY,NCT04058132,Phase 2,0.37663002844091975,0.6233699715590804
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,PREECLAMPSIA,NCT03724838,Not Applicable,0.06938376827175913,0.930616231728241
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,BIRTH ASPHYXIA,NCT04169191,Phase 1,0.30497997861339565,0.6950200213866046
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,_APIXABAN,PERSISTENT ATRIAL FIBRILLATION,NCT02633774,Not Applicable,0.12617157691694014,0.8738284230830599
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,_ESOMEPRAZOLE,PREECLAMPSIA,NCT03717701,Not Applicable,0.04488589505905148,0.9551141049409484
CCCC(CCC)C(=O)O,_VALPROIC_ACID,ACUTE MYELOID LEUKEMIA,NCT01369368,Phase 1|Phase 2,0.23024514188862605,0.7697548581113741
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,_CALCITONIN,MIGRAINE DISORDERS,NCT04019496,,0.5917955339011058,0.4082044660988942
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,_PYRIMETHAMINE,MYELODYSPLASTIC SYNDROME,NCT03057990,Phase 1,0.5478800720962219,0.4521199279037781
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_CHLOROQUINE,COVID-19 PNEUMONIA,NCT04428268,Phase 2,0.002665065541286064,0.9973349344587141
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O,_CHLOROQUINE_PHOSPHATE,COVID-19 PNEUMONIA,NCT04428268,Phase 2,0.046092298549456866,0.9539077014505434
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,_SULFADOXINE,MALARIA IN PREGNANCY,NCT03998839,,0.20439415839413,0.7956058416058702
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,_PROCALCITONIN,PNEUMONIA,NCT03711227,,0.7426530316575759,0.25734696834242365
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,_IVERMECTIN,CORONAVIRUS INFECTION,NCT04431466,Phase 2,0.03625783549270021,0.9637421645073001
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,_IVERMECTIN,MALARIA,NCT03967054,Phase 3,0.022689408237509773,0.9773105917624904
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,_IVERMECTIN,CORONAVIRUS INFECTIONS,NCT04384458,Not Applicable,0.03625783549270021,0.9637421645073001
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,_LOPINAVIR,COVID-19 PNEUMONIA,NCT04346147,Phase 2,0.05432523605821949,0.9456747639417808
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAMPIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.01827180432401326,0.9817281956759868
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAMPICIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.01827180432401326,0.9817281956759868
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,PARKINSON'S DISEASE,NCT04342273,Phase 1,0.2575946649534877,0.7424053350465124
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,SCHIZOPHRENIA,NCT04369391,Phase 1,0.3132217261977485,0.6867782738022516
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,DIABETES,NCT01984827,Phase 1,0.2743835878720868,0.7256164121279133
CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,_CLOFAZIMINE,MYCOBACTERIUM AVIUM COMPLEX,NCT02968212,Phase 2,0.3278576252831084,0.6721423747168916
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,_IMIPENEM,PNEUMONIA,NCT03177720,Phase 1,0.01735496977796842,0.9826450302220318
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,_ROFLUMILAST,ASTHMA,NCT04108377,Phase 1,0.4217528809090673,0.5782471190909331
[Cl-].[Na+],_SODIUM_CHLORIDE,CROHN'S DISEASE,NCT03681067,Phase 1|Phase 2,0.13793347200461845,0.8620665279953817
[Cl-].[Na+],_SODIUM_CHLORIDE,EPISTAXIS,NCT02930941,Not Applicable,0.06122264693932365,0.9387773530606764
[Cl-].[Na+],_SODIUM_CHLORIDE,CHRONIC HEPATITIS B,NCT04465890,Phase 2,0.12496519284508865,0.8750348071549117
[Cl-].[Na+],_SODIUM_CHLORIDE,ALLERGIC ASTHMA,NCT04035109,Phase 1|Phase 2,0.19860322648647305,0.8013967735135271
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.03968755787485924,0.9603124421251408
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,INFECTION,NCT03844776,Not Applicable,0.0957156788710008,0.9042843211289991
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,PERIODONTITIS,NCT03733379,Phase 3,0.023706945378292998,0.9762930546217068
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,LIVER CIRRHOSIS,NCT03005444,Not Applicable,0.08992999833437416,0.910070001665626
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,TYPE 1 DIABETES,NCT03228732,Early Phase 1,0.14237305650129425,0.8576269434987062
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,_DULOXETINE,OSTEO ARTHRITIS OF THE KNEES,NCT04224584,Phase 2,0.11299178200122455,0.8870082179987757
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,_ERTAPENEM,URINARY TRACT INFECTIONS,NCT03218800,Phase 3,0.08222146331501935,0.9177785366849808
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,DYSPEPSIA,NCT02621359,Phase 3,0.2582950246026755,0.7417049753973246
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.1410236402501855,0.8589763597498146
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT02067780,Phase 2,0.1410236402501855,0.8589763597498146
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,_LAMIVUDINE,COLORECTAL CANCER METASTATIC,NCT03144804,Phase 2,0.4865375297362293,0.5134624702637707
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,_LAMIVUDINE,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT03528941,,0.2672984411034464,0.7327015588965539
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,FRAGILE X SYNDROME,NCT02998151,Phase 2,0.6341210812597357,0.365878918740264
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,HYPERTENSION,NCT02133872,Phase 1,0.6373956615299236,0.3626043384700761
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.5520270822328521,0.4479729177671479
CC(C)C[C@H](CN)CC(=O)O,_PREGABALIN,NAUSEA,NCT04181346,Phase 2,0.05209537685023905,0.9479046231497612
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,_CAPSAICIN,PARKINSON'S DISEASE,NCT03321019,,0.516105879815775,0.483894120184225
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,_CAPSAICIN,AMYOTROPHIC LATERAL SCLEROSIS,NCT02962050,,0.516105879815775,0.483894120184225
NC(=O)N1c2ccccc2C=Cc2ccccc21,_CARBAMAZEPINE,TRIGEMINAL NEURALGIA,NCT03580317,Not Applicable,0.06773219861480892,0.9322678013851912
NS(=O)(=O)Cc1noc2ccccc12,_ZONISAMIDE,PARKINSON'S DISEASE,NCT04182399,Not Applicable,0.3634892083112041,0.6365107916887959
CC[C@@H](C(N)=O)N1CCCC1=O,_LEVETIRACETAM,SCHIZOPHRENIA,NCT02647437,Not Applicable,0.13918051551608496,0.8608194844839153
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,_RUFINAMIDE,LENNOX-GASTAUT SYNDROME,NCT02175173,,0.6176438088095467,0.3823561911904532
N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,_PERAMPANEL,AMYOTROPHIC LATERAL SCLEROSIS,NCT03793868,Early Phase 1,0.3712876452976265,0.6287123547023735
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,PARKINSON'S DISEASE,NCT03582137,Phase 2,0.4446607005089154,0.5553392994910845
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,ANXIETY,NCT02548559,Phase 2,0.8197121625069012,0.18028783749309865
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,CHRONIC PAIN,NCT04044729,Early Phase 1,0.4478869607386913,0.5521130392613087
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,PRADER-WILLI SYNDROME,NCT03458416,Phase 2,0.8911905673662528,0.1088094326337471
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,_NITAZOXANIDE,DYSPEPSIA,NCT02621359,Phase 3,0.2694020240257561,0.7305979759742443
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,_NITAZOXANIDE,CHRONIC HEPATITIS B,NCT03905655,Phase 2,0.335167035528468,0.6648329644715325
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,_OLANZAPINE,GASTRIC CANCER,NCT03575637,Phase 2,0.10223971445511644,0.8977602855448836
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,_RISPERIDONE,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.10154705243552868,0.8984529475644715
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,_RISPERIDON,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.1872436535102969,0.8127563464897031
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,_COLCHICINE,CORONAVIRUS INFECTION,NCT04363437,Phase 2,0.27016526477925223,0.7298347352207479
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,_COLCHICINE,CORONA VIRUS INFECTION,NCT04322682,Phase 3,0.3583097304831149,0.6416902695168851
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,_COLCHICINE,AMYOTROPHIC LATERAL SCLEROSIS,NCT03693781,Phase 2,0.1608477780470942,0.8391522219529057
CC(C)Cn1cnc2c(N)nc3ccccc3c21,_IMIQUIMOD,METASTATIC BREAST CANCER,NCT03982004,Phase 1,0.4216310933274582,0.5783689066725417
CC(C)Cn1cnc2c(N)nc3ccccc3c21,_IMIQUIMOD,"LYMPHOMA, T-CELL, CUTANEOUS",NCT03116659,Early Phase 1,0.4807103720448792,0.5192896279551209
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,_CEPHALEXIN,CYSTIC FIBROSIS,NCT04553419,Phase 3,0.07396748681580098,0.9260325131841992
O=NN(CCCl)C(=O)NCCCl,_CARMUSTINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.9957220603039576,0.004277939696042368
Oc1ncnc2[nH]ncc12,_ALLOPURINOL,CHRONIC KIDNEY DISEASE,NCT03990363,Phase 2,0.29128324040097303,0.7087167595990275
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,MULTIPLE MYELOMA,NCT03406091,,0.4129398633025058,0.5870601366974944
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.4987241916612843,0.5012758083387157
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,"DIABETES MELLITUS, TYPE 1",NCT03182426,Phase 1|Phase 2,0.2694637286433945,0.7305362713566061
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03736616,Phase 2,0.7987946348145347,0.20120536518546508
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,NON HODGKIN LYMPHOMA,NCT02180711,Phase 1|Phase 2,0.8490375064884575,0.15096249351154206
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,INFECTIOUS DISEASES,NCT04489797,Phase 1,0.7597661551467617,0.24023384485323784
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,PROSTATE CANCER,NCT02944201,Phase 2,0.4293839995909632,0.5706160004090367
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,BREAST CANCER,NCT03879629,Phase 2,0.2321708770154177,0.7678291229845824
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,ESOPHAGEAL VARICES,NCT04499898,Phase 2|Phase 3,0.009774360046837538,0.9902256399531624
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,_ETOPOSIDE_PHOSPHATE,LYMPHOMA,NCT02106988,Phase 2,0.6855216861595648,0.31447831384043523
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,_MOMETASONE,SICKLE CELL DISEASE,NCT03758950,Phase 2,0.21700047956634674,0.7829995204336535
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,PANCREATIC CANCER,NCT03434678,Phase 3,0.12546218291001948,0.8745378170899807
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,HEART FAILURE,NCT02421341,Not Applicable,0.12546218291001948,0.8745378170899807
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,ANALGESIA,NCT04442906,Not Applicable,0.01480887265727426,0.9851911273427256
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,POSTOPERATIVE DELIRIUM,NCT03120442,Not Applicable,0.010972489874596886,0.9890275101254029
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,_ONDANSETRON,CHOLECYSTITIS,NCT04468685,Phase 2,0.1822671885004978,0.8177328114995024
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,COLORECTAL CANCER,NCT03273231,Not Applicable,0.007746941741319445,0.9922530582586806
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,FATIGUE,NCT04141696,Phase 1|Phase 2,0.1376643979593643,0.8623356020406358
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,POST-TRAUMATIC STRESS DISORDER,NCT03960658,Phase 1|Phase 2,0.4764121774289015,0.5235878225710985
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,TINNITUS,NCT03336398,Phase 2,0.05065417602113501,0.949345823978865
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,SUBARACHNOID HEMORRHAGE,NCT02636218,Phase 2|Phase 3,0.10602448162397188,0.8939755183760282
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,CLUSTER HEADACHE,NCT04179266,Phase 1|Phase 2,0.29865415693883546,0.7013458430611648
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,PANCREATIC CANCER,NCT03434678,Phase 3,0.04008221155107775,0.9599177884489224
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,ANALGESIA,NCT03922048,Phase 2,0.2027407954008152,0.7972592045991849
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,THYROID DISEASES,NCT04471597,Not Applicable,0.012789021797485195,0.9872109782025148
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,_LIDOCAINE_HYDROCHLORIDE,PANCREATIC CANCER,NCT04048278,Early Phase 1,0.1903872971337108,0.8096127028662893
CC(C)c1cccc(C(C)C)c1O,_PROPOFOL,PANCREATIC CANCER,NCT03434678,Phase 3,0.05628979942299443,0.9437102005770056
CC(C)c1cccc(C(C)C)c1O,_PROPOFOL,CRITICAL ILLNESS,NCT03653832,Phase 3,0.035435888580447335,0.9645641114195526
CC(C)c1cccc(C(C)C)c1O,_PROPOFOL,POSTOPERATIVE DELIRIUM,NCT03120442,Not Applicable,0.011414843268862374,0.9885851567311376
CNCCC=C1c2ccccc2CCc2ccccc21,_NORTRIPTYLINE,FUNCTIONAL DYSPEPSIA,NCT03652571,Phase 3,0.09929101628223894,0.9007089837177611
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,AGE-RELATED MACULAR DEGENERATION,NCT04292756,Not Applicable,0.00197619080779801,0.998023809192202
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,ASTHMA IN CHILDREN,NCT04002362,Phase 2,0.23391814502497024,0.76608185497503
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,PSORIASIS,NCT04117919,Phase 2,0.00197619080779801,0.998023809192202
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,_TRIAMCINOLONE_ACETONIDE,AGE-RELATED MACULAR DEGENERATION,NCT04292756,Not Applicable,0.027186355281373264,0.9728136447186267
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,_TRIAMCINOLONE_ACETONIDE,ASTHMA IN CHILDREN,NCT04002362,Phase 2,0.4614942033590051,0.538505796640995
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,_GUANFACINE,ALZHEIMER DISEASE,NCT03116126,Phase 3,0.2400949330477713,0.7599050669522288
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,_GUANFACINE,TRIGEMINAL NEURALGIA,NCT03865940,Phase 2,0.1869275749694804,0.8130724250305198
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,_OXYCODONE,PARKINSON'S DISEASE,NCT02601586,Phase 2|Phase 3,0.08248604304710842,0.9175139569528916
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,_OXYCODONE,COLORECTAL CANCER,NCT03253133,Phase 1,0.24706549141433484,0.7529345085856651
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,_DIAZEPAM,CONTRACEPTION,NCT02799641,Not Applicable,0.18058924092763146,0.8194107590723688
O=C([O-])O.[Na+],_SODIUM_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.04866988826924462,0.9513301117307555
O=C(O)O,_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.4053925823099265,0.5946074176900737
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.2172069062702104,0.7827930937297899
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,ACUTE MYELOID LEUKEMIA,NCT02942758,Phase 2,0.06568360783176731,0.9343163921682328
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,CHRONIC MYELOID LEUKEMIA,NCT02889003,Phase 2,0.11054450445734824,0.8894554955426518
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,OBESITY,NCT03866408,Early Phase 1,0.14415584544077004,0.8558441545592302
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,GASTROPARESIS,NCT04300127,Early Phase 1,0.32661545658678875,0.6733845434132113
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,_TIMOLOL,PRIMARY OPEN ANGLE GLAUCOMA,NCT03193333,Phase 3,0.029331571889514917,0.9706684281104851
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,_TIMOLOL,"GLAUCOMA, PRIMARY OPEN ANGLE|OCULAR HYPERTENSION",NCT04149899,Phase 1|Phase 2,0.04685441722597727,0.9531455827740228
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,_LATANOPROST,OPEN ANGLE GLAUCOMA,NCT04060758,Phase 1,0.08108190675579102,0.9189180932442091
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,_DORZOLAMIDE,PRIMARY OPEN ANGLE GLAUCOMA,NCT03193333,Phase 3,0.1999733336515604,0.8000266663484398
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,_BIMATOPROST,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT04285580,Phase 3,0.2444185166781482,0.7555814833218519
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,_BLEOMYCIN,GASTRIC CANCER,NCT04139070,Phase 1,0.8505293579907316,0.14947064200926807
CN(C)/N=N/c1[nH]cnc1C(N)=O,_DACARBAZINE,HODGKIN LYMPHOMA,NCT03033914,Phase 1|Phase 2,0.323589625169754,0.6764103748302461
O=S(=O)(O)CCS,_MESNA,LYMPHOMA,NCT02436707,Phase 2,0.24062474715268,0.75937525284732
O=S(=O)(O)CCS,_MESNA,SICKLE CELL DISEASE,NCT03263559,Phase 2,0.5089117246833854,0.4910882753166144
O=S(=O)(O)CCS,_MESNA,RETINOBLASTOMA,NCT01783535,Phase 2,0.3422652735298479,0.6577347264701519
O=S(=O)(O)CCS,_MESNA,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.4818269744237398,0.5181730255762601
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,PREECLAMPSIA,NCT02221830,Early Phase 1,0.20888761927160432,0.7911123807283961
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,OBESITY,NCT03043053,Phase 2,0.20317727874782204,0.7968227212521782
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,TINNITUS,NCT04210310,Not Applicable,0.18001451952374606,0.8199854804762542
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,POSTOPERATIVE PAIN,NCT03011307,Phase 2,0.18001451952374606,0.8199854804762542
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,NEUROPATHIC PAIN,NCT02100956,Phase 2,0.1553139486657895,0.8446860513342108
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,PRADER-WILLI SYNDROME,NCT03114371,Not Applicable,0.14777900173549666,0.8522209982645035
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,ATTENTION DEFICIT/HYPERACTIVITY DISORDER,NCT03136263,Early Phase 1,0.17996822443054564,0.8200317755694546
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,_ROCURONIUM,PROSTATE CANCER,NCT03808077,Phase 2,0.2262631577426544,0.773736842257346
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,_ROCURONIUM,PANCREATIC CANCER,NCT03434678,Phase 3,0.22094550646989175,0.7790544935301085
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,_ROCURONIUM,CRITICAL ILLNESS,NCT03791801,Not Applicable,0.14984133735822364,0.8501586626417764
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,_NALBUPHINE,POSTOPERATIVE COMPLICATIONS,NCT03470077,Phase 2,0.11040275698725104,0.889597243012749
CCCN[C@H]1CCc2nc(N)sc2C1,_PRAMIPEXOLE,CHRONIC PAIN,NCT03842709,Early Phase 1,0.2327675685624957,0.7672324314375045
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,PAIN,NCT04034004,Early Phase 1,0.1919355627981797,0.8080644372018203
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,"DIABETES MELLITUS, TYPE 1",NCT03149770,Phase 2,0.1919355627981797,0.8080644372018203
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,EPILEPSY,NCT02332447,Phase 3,0.1154443511008386,0.8845556488991615
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,_IOHEXOL,ACUTE KIDNEY INJURY,NCT02772276,Phase 2,0.3757635910054936,0.6242364089945063
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,GASTRIC CANCER,NCT04205097,Not Applicable,0.08822073298633287,0.9117792670136672
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,CRITICAL ILLNESS,NCT03791801,Not Applicable,0.09832060946102,0.9016793905389799
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,POSTOPERATIVE PAIN,NCT04544228,Not Applicable,0.10770738410884663,0.8922926158911535
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,_TENOFOVIR_ALAFENAMIDE,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.6245378791296531,0.3754621208703468
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,_TENOFOVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.3477356634557877,0.6522643365442121
COc1cc(CC(C)N)c(OC)cc1C,_DOM,CHRONIC HEPATITIS B,NCT02287857,Not Applicable,0.2734754510122233,0.726524548987777
COc1cc(CC(C)N)c(OC)cc1C,_DOM,STROKE,NCT03828851,Not Applicable,0.0935643159447856,0.9064356840552148
COc1cc(CC(C)N)c(OC)cc1C,_DOM,GASTROPARESIS,NCT03810287,Early Phase 1,0.6144026193760044,0.385597380623995
COc1cc(CC(C)N)c(OC)cc1C,_DOM,HEMOPHILIA A,NCT03818763,Phase 1,0.6122014719983003,0.38779852800169934
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,_SOFOSBUVIR,HEPATITIS B INFECTION,NCT03312023,Phase 2,0.4152004031104265,0.5847995968895736
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C,_LEDIPASVIR,HEPATITIS B INFECTION,NCT03312023,Phase 2,0.3675165926898369,0.6324834073101634
CS(=O)(=O)O.Nc1ncnc2c1ncn2CCOC[P@@]1(=O)OCC[C@@H](c2cccc(Cl)c2)O1,_PRADEFOVIR_MESYLATE,CHRONIC HEPATITIS B,NCT04543565,Phase 3,0.32588682212344994,0.6741131778765503
Nc1ncnc2c1ncn2CCOC[P@@]1(=O)OCC[C@@H](c2cccc(Cl)c2)O1,_PRADEFOVIR,CHRONIC HEPATITIS B,NCT04543565,Phase 3,0.31976146611538897,0.6802385338846112
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,EPISTAXIS,NCT02930941,Not Applicable,0.04564763138128053,0.9543523686187196
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,_ISOMALT,IRON DEFICIENCY ANEMIA TREATMENT,NCT03610230,Not Applicable,0.17642380670466326,0.8235761932953367
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,_MITOMYCIN,COLORECTAL CANCER,NCT02614534,Phase 3,0.06653478270361718,0.933465217296383
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],_SODIUM_THIOSULFATE,CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT00293475,Phase 1|Phase 2,0.9247862965707904,0.07521370342920931
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,_VANDETANIB,NEOPLASMS,NCT02530411,Phase 2,0.2887016183216275,0.7112983816783724
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,_FAMOTIDINE,LYMPHOMA,NCT03647072,Phase 3,0.09839406154427258,0.9016059384557276
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,_FAMOTIDINE,EOSINOPHILIC ESOPHAGITIS,NCT04248712,Phase 2,0.20917372193861525,0.7908262780613852
[Cl-].[K+],_POTASSIUM_CHLORIDE,HEART FAILURE,NCT02840799,Phase 2,0.1837161838048439,0.8162838161951561
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],_MAGNESIUM_CITRATE,DIABETIC NEPHROPATHY,NCT03824379,Phase 2,0.11826462407320028,0.8817353759268001
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,_BROMOCRIPTINE,OBESITY,NCT03525002,Phase 2,0.16392267812402622,0.8360773218759736
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,_BROMOCRIPTINE,PERIPARTUM CARDIOMYOPATHY,NCT02590601,Phase 3,0.18894662372694931,0.8110533762730506
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,_LORATADINE,EOSINOPHILIC ESOPHAGITIS,NCT04248712,Phase 2,0.3981028699229461,0.6018971300770537
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,_GEFITINIB,STOMACH NEOPLASMS,NCT03170180,Phase 2,0.22464529548458045,0.7753547045154199
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,_LAPATINIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.8978186213100255,0.10218137868997418
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,_CRIZOTINIB,NON SMALL CELL LUNG CANCER,NCT03375242,,0.5118028935219087,0.4881971064780914
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,_CRIZOTINIB,NEOPLASMS,NCT03194893,Phase 3,0.4353239913280891,0.564676008671911
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,NON SMALL CELL LUNG CANCER,NCT03267654,Phase 2,0.3386563627634901,0.6613436372365102
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,PANCREATIC CANCER,NCT04415385,Phase 2,0.03824536537806269,0.9617546346219374
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,COLORECTAL CANCER,NCT04446091,Phase 1|Phase 2,0.14055876720108818,0.8594412327989118
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,GLIOBLASTOMA,NCT03567135,,0.23374536227899445,0.7662546377210055
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,HEPATOCELLULAR CARCINOMA,NCT04411706,Phase 2,0.03824536537806269,0.9617546346219374
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,HEAD AND NECK NEOPLASMS,NCT02989259,Phase 2,0.03824536537806269,0.9617546346219374
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,GLIOMA,NCT03741244,Phase 2,0.1406142710905559,0.8593857289094444
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,NON SMALL CELL LUNG CANCER,NCT03267654,Phase 2,0.3386563627634901,0.6613436372365102
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,PANCREATIC CANCER,NCT04415385,Phase 2,0.03824536537806269,0.9617546346219374
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,COLORECTAL CANCER,NCT04446091,Phase 1|Phase 2,0.14055876720108818,0.8594412327989118
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,GLIOBLASTOMA,NCT03567135,,0.23374536227899445,0.7662546377210055
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,HEPATOCELLULAR CARCINOMA,NCT04411706,Phase 2,0.03824536537806269,0.9617546346219374
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,HEAD AND NECK NEOPLASMS,NCT02989259,Phase 2,0.03824536537806269,0.9617546346219374
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,GLIOMA,NCT03741244,Phase 2,0.1406142710905559,0.8593857289094444
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,_ICOTINIB,METASTATIC BREAST CANCER,NCT02362230,Phase 2,0.3067955278207985,0.6932044721792018
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,_ICOTINIB,NON-SQUAMOUS NSCLC,NCT03992885,Phase 3,0.29432886424764504,0.7056711357523554
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,OVARIAN CANCER,NCT03763123,Phase 1,0.3188393670139094,0.6811606329860908
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,SMALL CELL LUNG CANCER,NCT03088813,Phase 2|Phase 3,0.3527390182795823,0.6472609817204177
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,RETINOBLASTOMA,NCT01783535,Phase 2,0.3523139051439784,0.647686094856022
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,_TALAZOPARIB,BREAST CANCER,NCT04039230,Phase 1|Phase 2,0.7882596546575792,0.2117403453424206
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,_TALAZOPARIB,PANCREATIC CANCER,NCT03637491,Phase 2,0.8038466855226551,0.19615331447734444
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,_TALAZOPARIB,ACUTE MYELOID LEUKEMIA,NCT02878785,Phase 1|Phase 2,0.8073050607915038,0.19269493920849598
CCN(CC)C(=S)SSC(=S)N(CC)CC,_DISULFIRAM,GLIOBLASTOMA,NCT03151772,Early Phase 1,0.24289124170414,0.7571087582958603
CCN(CC)C(=S)SSC(=S)N(CC)CC,_DISULFIRAM,METASTATIC BREAST CANCER,NCT04265274,Phase 2,0.4094966830657386,0.5905033169342615
CCN(CC)C(=S)SSC(=S)N(CC)CC,_DISULFIRAM,GLIOBLASTOMA MULTIFORME,NCT02715609,Phase 1|Phase 2,0.4748141403409616,0.5251858596590383
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,END STAGE RENAL DISEASE,NCT03713190,Phase 2,0.09433085560045948,0.9056691443995408
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,TYPE 1 DIABETES,NCT04201496,Phase 1,0.3186214176047472,0.6813785823952528
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,CHRONIC KIDNEY DISEASE,NCT03594110,Phase 3,0.2529517285297427,0.7470482714702572
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,_ERTUGLIFLOZIN,TYPE 2 DIABETES,NCT04029480,Phase 3,0.5403426051302603,0.4596573948697395
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,_EVOGLIPTIN,"DIABETES MELLITUS, TYPE 2",NCT04326166,,0.3585630533104547,0.6414369466895452
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,_MARAVIROC,STROKE,NCT03172026,Phase 2|Phase 3,0.2639409437616465,0.736059056238354
CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,_MEMANTINE_HYDROCHLORIDE,SICKLE CELL DISEASE,NCT03247218,Phase 2,0.2896851629307282,0.7103148370692719
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.047991815436053416,0.9520081845639468
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.052720991217092686,0.9472790087829074
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,PULMONARY HYPERTENSION,NCT03270332,Early Phase 1,0.1090405288801184,0.8909594711198817
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.047991815436053416,0.9520081845639468
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.052720991217092686,0.9472790087829074
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,PULMONARY HYPERTENSION,NCT03270332,Early Phase 1,0.1090405288801184,0.8909594711198817
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,PARKINSON'S DISEASE,NCT04164758,Phase 2,0.1819029237408584,0.8180970762591419
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,POSTOPERATIVE DELIRIUM,NCT03739476,Phase 3,0.10720557562457923,0.8927944243754209
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,_LURASIDONE,BIPOLAR DISORDER,NCT02731612,Phase 3,0.3244525644333725,0.6755474355666274
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,_APREPITANT,NON SMALL CELL LUNG CANCER,NCT02646020,Phase 2,0.0732293430838973,0.9267706569161028
C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,_FOSAPREPITANT,MULTIPLE MYELOMA,NCT02780609,Phase 1|Phase 2,0.6916164684320006,0.30838353156799914
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,CRITICAL ILLNESS,NCT02285751,Phase 2,0.01067590977815641,0.9893240902218436
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,DIABETES MELLITUS TYPE 2,NCT04305587,Phase 1,0.0997390458388068,0.9002609541611933
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,_RABEPRAZOLE,INFECTIOUS DISEASES,NCT04489797,Phase 1,0.19851184343734335,0.8014881565626568
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,_LACTOSE,CRITICAL ILLNESS,NCT03464708,Phase 2,0.18126362338520072,0.8187363766147996
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,_MEGESTROL_ACETATE,BREAST CANCER,NCT03306472,Phase 2,0.15533627433674468,0.8446637256632556
NCCCC[C@H](N)C(=O)O,_LYSINE,HEART FAILURE,NCT03446651,Early Phase 1,0.5973895047928537,0.402610495207146
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,_ARTESUNATE,COLORECTAL CANCER,NCT03093129,Phase 2,0.02309585042097984,0.9769041495790202
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,_MOCETINOSTAT,RHABDOMYOSARCOMA,NCT04299113,Phase 1,0.81384304880475,0.18615695119525
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1,_PIRARUBICIN,SOFT TISSUE SARCOMA,NCT04126811,Phase 2,0.0944808009635206,0.9055191990364791
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],_PEMETREXED_DISODIUM,NON SMALL CELL LUNG CANCER,NCT04379635,Phase 3,0.5042786335613111,0.4957213664386888
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,_DOBUTAMINE,MYOCARDIAL INFARCTION,NCT03289728,Not Applicable,0.08627566513176436,0.913724334868236
CN1CCN2c3ncccc3Cc3ccccc3C2C1,_MIRTAZAPINE,BREAST CANCER,NCT02336750,Phase 3,0.10307290767216802,0.8969270923278322
Brc1c(NC2=NCCN2)ccc2nccnc12,_BRIMONIDINE,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT03450629,Phase 3,0.15757648137290667,0.8424235186270934
Brc1c(NC2=NCCN2)ccc2nccnc12,_BRIMONIDINE,PRIMARY OPEN ANGLE GLAUCOMA,NCT03193333,Phase 3,0.13037791695297402,0.8696220830470262
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,_RIOCIGUAT,SICKLE CELL DISEASE,NCT02633397,Phase 2,0.26988120064672616,0.7301187993532742
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,_EPLERENONE,HIV INFECTION,NCT02740179,Not Applicable,0.08382055457047045,0.9161794454295298
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,_EPLERENONE,END-STAGE RENAL DISEASE,NCT02490904,Phase 3,0.027772809955773862,0.9722271900442262
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,NEPHROTIC SYNDROME,NCT03750136,Not Applicable,0.16882845535205376,0.8311715446479464
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,_CERITINIB,NON SMALL CELL LUNG CANCER,NCT03087448,Phase 1|Phase 2,0.9694960690366536,0.03050393096334652
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,_CERITINIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.5710334299262828,0.4289665700737171
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,_AXITINIB,GASTROINTESTINAL STROMAL TUMORS,NCT04258956,Phase 2,0.7601017210006045,0.2398982789993953
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,_TIVOZANIB,HEPATOCELLULAR CARCINOMA,NCT03970616,Phase 1|Phase 2,0.8612633095010778,0.1387366904989222
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,_ALPRAZOLAM,TYPE 1 DIABETES,NCT03635437,Phase 1|Phase 2,0.15644819585037914,0.8435518041496209
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,_MUPIROCIN,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.29787018447951424,0.7021298155204856
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,BREAST CANCER,NCT02395614,Not Applicable,0.20680829861850786,0.7931917013814923
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,INFECTION,NCT03844776,Not Applicable,0.06937929543832412,0.9306207045616759
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.3283206589004994,0.6716793410995006
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,PERI-IMPLANTITIS,NCT03977324,Not Applicable,0.023362571228161277,0.9766374287718388
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_CHLORHEXIDINE_GLUCONATE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.5277166734130612,0.4722833265869388
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,_SULFAMETHOXAZOLE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.3781588780476221,0.6218411219523782
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,_PARICALCITOL,PANCREATIC CANCER,NCT04054362,Phase 2,0.3415279148055241,0.6584720851944763
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,_ZOLPIDEM,PROSTATIC NEOPLASMS,NCT03436745,Phase 1,0.3387705436292113,0.661229456370789
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_MANNITOL,CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT00293475,Phase 1|Phase 2,0.69184052046912,0.3081594795308798
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_MANNITOL,SUBARACHNOID HEMORRHAGE,NCT04135456,Not Applicable,0.3799891011909515,0.6200108988090484
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O,_CEFTAZIDIME,BACTERIAL INFECTION,NCT03978091,Phase 1,0.3487931455120165,0.6512068544879837
O=NN(CCCl)C(=O)NC1CCCCC1,_LOMUSTINE,GLIOBLASTOMA MULTIFORME,NCT04421378,Phase 1|Phase 2,0.9082361032801844,0.09176389671981544
CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,_ENTRECTINIB,NON SMALL CELL LUNG CANCER,NCT03178552,Phase 2|Phase 3,0.7044666601673538,0.2955333398326461
O=c1[nH]c(=O)n(C2CCCO2)cc1F,_TEGAFUR,GASTRIC CANCER,NCT03006705,Phase 3,0.5607280231459874,0.4392719768540125
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,_GALETERONE,ADVANCED PANCREATIC CANCER,NCT04098081,Phase 2,0.5040263901541308,0.4959736098458693
Nc1nc(=O)c2c([nH]1)NC[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,_FOLINIC_ACID,COLORECTAL CANCER METASTATIC,NCT03751176,Phase 2,0.6395024424817386,0.36049755751826096
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,_TRABECTEDIN,SOFT TISSUE SARCOMA,NCT02367924,,0.8932086660623806,0.10679133393761914
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_ALDOXORUBICIN,PANCREATIC CANCER,NCT04390399,Phase 2,0.9095129801818778,0.09048701981812204
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,_CEDIRANIB,NON SMALL CELL LUNG CANCER,NCT03334617,Phase 2,0.7262973618695772,0.2737026381304226
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_BETAMETHASONE,PREMATURE BIRTH,NCT02469519,Phase 2|Phase 3,0.041180750308908935,0.9588192496910912
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](O)C2CC2)C[C@@H](O)C[C@@H]1O,_CALCIPOTRIENE,BREAST CANCER,NCT03596073,Phase 1,0.3594032548714667,0.6405967451285335
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](O)C2CC2)C[C@@H](O)C[C@@H]1O,_CALCIPOTRIOL,BREAST CANCER,NCT03596073,Phase 1,0.3594032548714667,0.6405967451285335
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,SICKLE CELL DISEASE,NCT03978156,Phase 1,0.19017638980091595,0.8098236101990841
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,ALZHEIMER DISEASE,NCT02792257,Phase 2,0.19058539364251936,0.8094146063574809
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,OSTEO ARTHRITIS OF THE KNEES,NCT04298528,Phase 3,0.19058539364251936,0.8094146063574809
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,CHRONIC PAIN,NCT03766269,Phase 2,0.5360222120688706,0.4639777879311293
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,BIPOLAR DISORDER,NCT04231643,Early Phase 1,0.2860520341151179,0.7139479658848823
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,_RUPATADINE,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.2695784591973701,0.7304215408026302
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,_UMBRALISIB,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT04016805,Phase 2,0.709073868244426,0.2909261317555737
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,_BRIMONIDINE_TARTRATE,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT03450629,Phase 3,0.4289020275962136,0.5710979724037865
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,_NABILONE,PARKINSON'S DISEASE,NCT03773796,Phase 3,0.2507269484906157,0.7492730515093845
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,_COENZYME_Q1,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.27818088310525474,0.7218191168947456
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,_RIBAVIRIN,ACUTE MYELOID LEUKEMIA,NCT03760666,Phase 1|Phase 2,0.17775484478982906,0.8222451552101709
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,_RIBAVIRIN,"HEPATITIS B, CHRONIC",NCT03759782,Phase 3,0.04803009189981377,0.9519699081001864
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,PARKINSON'S DISEASE,NCT03575195,Phase 1|Phase 2,0.058886866667696075,0.9411131333323041
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,TYPE 2 DIABETES,NCT03758144,Not Applicable,0.02639900415797699,0.9736009958420229
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,_QUINIDINE,AMYOTROPHIC LATERAL SCLEROSIS,NCT03883581,Phase 1|Phase 2,0.4297891199241111,0.5702108800758889
NC(=O)NO,_HYDROXYUREA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.3543822841253311,0.6456177158746687
NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O,_PEVONEDISTAT,NON SMALL CELL LUNG CANCER,NCT03228186,Phase 2,0.7628515775626964,0.2371484224373033
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,_URSODIOL,LIVER DISEASES,NCT02943707,Phase 2,0.2733020405475101,0.7266979594524902
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,_URSODEOXYCHOLIC_ACID,LIVER DISEASES,NCT02943707,Phase 2,0.2733020405475101,0.7266979594524902
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,_BOSUTINIB,CHRONIC MYELOID LEUKEMIA,NCT03831776,Phase 2,0.3000740781843588,0.6999259218156414
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,_BOSUTINIB,CHRONIC MYELOGENOUS LEUKEMIA,NCT02501330,,0.3445489897487582,0.6554510102512421
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,_PENTOSTATIN,SICKLE CELL DISEASE,NCT03077542,Phase 1|Phase 2,0.4647199322915289,0.5352800677084709
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,_RIMIDUCID,MULTIPLE MYELOMA,NCT03288493,Phase 1|Phase 2,0.834178652483196,0.16582134751680358
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,_LEFLUNOMIDE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.04039986824256585,0.9596001317574344
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,_IDASANUTLIN,COLORECTAL CANCER,NCT03555149,Phase 1|Phase 2,0.935858126592904,0.06414187340709597
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,_PARSACLISIB,LYMPHOMA,NCT03235544,Phase 2,0.8109179872377521,0.18908201276224795
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,_TUCIDINOSTAT,BREAST CANCER,NCT04465097,Phase 2,0.3776454807113741,0.6223545192886261
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,_TUCIDINOSTAT,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04231448,Phase 3,0.4354752837649509,0.5645247162350491
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,_RUXOLITINIB_PHOSPHATE,MALARIA,NCT04456634,Phase 1,0.4292170722666173,0.5707829277333826
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,_NILOTINIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.12099555376166282,0.8790044462383372
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,_NILOTINIB,HUNTINGTON'S DISEASE,NCT03764215,Phase 1,0.3065498811674582,0.6934501188325417
COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1,_MEBENDAZOLE,COLORECTAL CANCER,NCT03925662,Phase 3,0.08873595605403888,0.9112640439459612
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,BREAST CANCER,NCT03911453,Early Phase 1,0.7337923578070535,0.2662076421929465
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,SMALL CELL LUNG CANCER,NCT03958045,Phase 2,0.7337923578070535,0.2662076421929465
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,PROSTATE CANCER METASTATIC,NCT03413995,Phase 2,0.7684372814920053,0.2315627185079943
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,_ZAFIRLUKAST,OVARIAN CANCER,NCT04339140,Phase 2,0.6734921023641572,0.32650789763584226
FC(F)(F)C(F)(F)C(F)(F)F,_PERFLUTREN,KIDNEY CANCER,NCT04021238,Phase 2,0.5941712004265379,0.405828799573462
FC(F)(F)C(F)(F)C(F)(F)F,_PERFLUTREN,HEPATOCELLULAR CARCINOMA|LIVER CANCER,NCT03199274,Early Phase 1,0.3409851611306675,0.6590148388693328
FS(F)(F)(F)(F)F,_SULFUR_HEXAFLUORIDE,KIDNEY CANCER,NCT04021238,Phase 2,0.6298658130362624,0.3701341869637373
O=[As]O[As]=O,_ARSENIC_TRIOXIDE,AML,NCT03031249,Phase 1|Phase 2,0.10691476152706526,0.8930852384729351
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,_TOFACITINIB,PSORIATIC ARTHRITIS,NCT03486457,Phase 3,0.17454433574964093,0.8254556642503591
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,GASTRIC CANCER,NCT04205097,Not Applicable,0.1738864208057832,0.826113579194217
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,CRITICAL ILLNESS,NCT03791801,Not Applicable,0.17702383284038364,0.8229761671596166
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,_LACTULOSE,CROHN'S DISEASE,NCT03962998,Early Phase 1,0.2006101693090213,0.7993898306909789
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,_FLUTICASONE,PHARMACOKINETICS,NCT03739294,Phase 2,0.09271697673647207,0.9072830232635279
CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3],_GADOTERIDOL,GLIOBLASTOMA,NCT02359097,Not Applicable,0.4995063539953547,0.5004936460046453
CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3],_GADOTERIDOL,MULTIPLE SCLEROSIS,NCT03396822,,0.4233296263960641,0.5766703736039358
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,GLIOBLASTOMA,NCT02359097,Not Applicable,0.6182720739436112,0.38172792605638856
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,CORONARY ARTERY DISEASE,NCT02954510,Phase 3,0.6279224392996993,0.3720775607003005
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,HYPERTENSION,NCT02425566,Phase 1,0.3816142954782607,0.6183857045217395
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,CARDIOVASCULAR DISEASE,NCT02115724,Not Applicable,0.30200662141005663,0.6979933785899435
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,COVID-19 PNEUMONIA,NCT04346147,Phase 2,0.21997429790634648,0.7800257020936537
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,UVEITIS,NCT04088409,Phase 3,0.4155623058106411,0.584437694189359
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,ALOPECIA AREATA,NCT03899259,Phase 3,0.3987094063378299,0.6012905936621702
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,_RADOTINIB,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",NCT03722420,Phase 3,0.5220847575497094,0.4779152424502906
CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,_TRIAMCINOLONE_HEXACETONIDE,OSTEO ARTHRITIS OF THE KNEES,NCT04231318,Phase 3,0.29868071832869986,0.7013192816713004
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,PROSTATE CANCER,NCT03716739,Phase 2,0.2195498136579055,0.7804501863420948
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,LIVER CIRRHOSIS,NCT03995251,Not Applicable,0.13727428285864196,0.8627257171413584
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_ENANTHATE,PROSTATE CANCER,NCT02090114,Phase 2,0.6495416813457673,0.3504583186542327
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,_KETOCONAZOLE,PROSTATE CANCER,NCT00859781,Phase 2,0.35707322757034243,0.6429267724296578
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,_NICLOSAMIDE,FAMILIAL ADENOMATOUS POLYPOSIS,NCT04296851,Phase 2,0.1985921719598069,0.8014078280401934
N[C@]1(C(=O)O)C[C@@H](F)C1,_FLUCICLOVINE,PROSTATE CANCER,NCT04009083,Not Applicable,0.35799258328175193,0.6420074167182479
N[C@]1(C(=O)O)C[C@@H](F)C1,_FLUCICLOVINE,GLIOBLASTOMA,NCT03926507,Early Phase 1,0.4198385736103949,0.5801614263896052
OC[C@H]1O[C@H](O[C@]2(CO[C@]3(CO[C@]4(CO[C@]5(CO[C@]6(CO[C@]7(CO[C@]8(CO[C@]9(CO[C@]%10(CO[C@]%11(CO[C@]%12(CO[C@]%13(CO[C@]%14(CO[C@]%15(CO[C@]%16(CO[C@]%17(CO[C@]%18(CO[C@]%19(CO[C@]%20(CO[C@]%21(CO[C@]%22(CO[C@]%23(CO[C@]%24(CO[C@]%25(CO[C@]%26(CO[C@]%27(CO[C@]%28(CO[C@]%29(CO[C@]%30(CO[C@]%31(CO[C@]%32(CO[C@]%33(CO[C@]%34(CO[C@]%35(CO[C@]%36(CO[C@]%37(CO[C@]%38(CO)O[C@H](CO)[C@@H](O)[C@@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_INULIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04459156,Not Applicable,0.22552563579920026,0.7744743642008001
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,_DESLORATADINE,NON SMALL CELL LUNG CANCER,NCT02646020,Phase 2,0.09406434099749644,0.9059356590025038
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,_LOPERAMIDE,COLORECTAL CANCER METASTATIC,NCT03705442,Phase 2,0.10947922598416987,0.8905207740158306
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,NON SMALL CELL LUNG CANCER,NCT02570815,Phase 1,0.16907730642475904,0.8309226935752411
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,HEPATOCELLULAR CARCINOMA,NCT04258566,Phase 1,0.618384757233426,0.38161524276657377
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,RHEUMATOID ARTHRITIS,NCT02680067,Phase 1,0.6286089052747514,0.3713910947252483
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,ENDOMETRIOSIS,NCT03950206,Not Applicable,0.16614382359275542,0.8338561764072446
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,_ATOVAQUONE,ACUTE MYELOID LEUKEMIA,NCT03568994,Early Phase 1,0.2604305796249157,0.7395694203750846
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,_GLASDEGIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.43690567260650204,0.5630943273934983
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,_GLASDEGIB,ACUTE MYELOID LEUKEMIA,NCT04051996,Phase 2,0.5839486042912071,0.4160513957087929
Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,_OXACILLIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.2575401963539117,0.7424598036460887
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],_GLYCOPYRROLATE,CRITICAL ILLNESS,NCT03791801,Not Applicable,0.2278004894248649,0.7721995105751353
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],_POTASSIUM_CITRATE,KIDNEY STONES,NCT03281928,Not Applicable,0.2184049303114368,0.7815950696885641
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,_HYALURONATE,GLAUCOMA,NCT03758859,Not Applicable,0.5076397603857895,0.4923602396142105
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,_TICAGRELOR,CRITICAL ILLNESS,NCT02285751,Phase 2,0.0881174646861682,0.9118825353138316
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,_PRASUGREL,CRITICAL ILLNESS,NCT02285751,Phase 2,0.2301896106173737,0.7698103893826266
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,_MELOXICAM,ANKYLOSING SPONDYLITIS,NCT04480359,Phase 2|Phase 3,0.11261440004361715,0.887385599956383
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],_COPPER_GLUCONATE,GLIOBLASTOMA MULTIFORME,NCT02715609,Phase 1|Phase 2,0.4794288652062999,0.5205711347937
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,NON SMALL CELL LUNG CANCER,NCT02642939,Phase 2,0.3748294247355058,0.625170575264494
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,BREAST CANCER,NCT02788981,Phase 2,0.26045549055864137,0.7395445094413589
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,_DONEPEZIL,"DIABETES MELLITUS, TYPE 2",NCT04507438,Phase 2,0.015145249520700628,0.9848547504792994
NCCS.O=C(O)C(O)C(O)C(=O)O,_CYSTEAMINE_BITARTRATE,ASTHMA,NCT03883984,Phase 1,0.3962928731079486,0.6037071268920517
CC(=O)C(=O)O,_PYRUVATE,PROSTATE CANCER,NCT02913131,Phase 1|Phase 2,0.38451269595919707,0.615487304040803
CC(=O)C(=O)O,_PYRUVATE,BREAST CANCER,NCT03121989,Phase 1,0.2859656181883425,0.7140343818116577
CC(=O)C(=O)O,_PYRUVATE,GLIOMA,NCT03739411,Phase 1,0.39508438247969213,0.6049156175203076
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,_PACRITINIB,BREAST CANCER,NCT04520269,Phase 1|Phase 2,0.7350054770608995,0.26499452293910003
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,_DANAZOL,IMMUNE THROMBOCYTOPENIA,NCT04481282,Phase 2,0.4459243483366768,0.5540756516633233
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,_BUMETANIDE,PARKINSON'S DISEASE,NCT03899324,Phase 2,0.37337134380237336,0.6266286561976266
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,_GRANISETRON,SEPSIS,NCT03924518,Phase 2,0.07524187988683237,0.924758120113168
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,_KETOTIFEN,FUNCTIONAL DYSPEPSIA,NCT02484248,Phase 3,0.1546828426282639,0.8453171573717364
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,_OXYMETAZOLINE,FECAL INCONTINENCE,NCT03529487,Phase 1,0.3384589306137735,0.6615410693862269
O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1,_CILOFEXOR,PRIMARY SCLEROSING CHOLANGITIS,NCT03890120,Phase 3,0.8729255109673341,0.12707448903266585
CCOC(=O)c1ccc(N)cc1,_BENZOCAINE,OBESITY,NCT02537314,Phase 1,0.2354575297301313,0.7645424702698689
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,_ILOPROST,"RESPIRATORY DISTRESS SYNDROME, ADULT",NCT03111212,Phase 3,0.12464933695613516,0.8753506630438649
Nc1ccc2cc3ccc(N)cc3nc2c1,_PROFLAVINE,BARRETT'S ESOPHAGUS,NCT02018367,Phase 2,0.3404436590129281,0.6595563409870722
CN(C)CCC=C1c2ccccc2COc2ccccc21,_DOXEPIN,BREAST CANCER,NCT02447211,Phase 2,0.2025965972349306,0.7974034027650694
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,_TERAZOSIN,PARKINSON'S DISEASE,NCT03905811,Phase 1|Phase 2,0.15725962904583388,0.8427403709541663
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,_FLUMAZENIL,PARKINSON'S DISEASE,NCT03462641,Phase 1|Phase 2,0.6011261621601367,0.3988738378398631
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,_DOMPERIDONE,GASTROPARESIS,NCT03810287,Early Phase 1,0.5111669299135693,0.4888330700864307
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,_ALBUTEROL_SULFATE,ASTHMA,NCT03847896,Phase 3,0.5403983799877923,0.4596016200122077
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,_PIMAVANSERIN,PARKINSON'S DISEASE,NCT04164758,Phase 2,0.4611159042074954,0.5388840957925047
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,_PIMAVANSERIN,SCHIZOPHRENIA,NCT04531982,Phase 3,0.42138071191381693,0.578619288086183
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,_TOMIVOSERTIB,BREAST CANCER,NCT04261218,Phase 1,0.7699497533579626,0.23005024664203705
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,_FOSTAMATINIB,OVARIAN CANCER,NCT03246074,Phase 1,0.712607734542419,0.2873922654575809
CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,_VISTUSERTIB,NON SMALL CELL LUNG CANCER,NCT03334617,Phase 2,0.7249310827051815,0.27506891729481825
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,_CAPMATINIB,NON SMALL CELL LUNG CANCER,NCT04139317,Phase 2,0.7262415263916401,0.27375847360835964
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,_CAPMATINIB,SOFT TISSUE SARCOMA,NCT03784014,Phase 3,0.5459151337909678,0.4540848662090322
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,_QUERCETIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT03989271,Phase 1|Phase 2,0.41746406860296587,0.5825359313970343
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,_QUERCETIN,ALZHEIMER DISEASE,NCT04063124,Phase 1|Phase 2,0.5195082872316268,0.4804917127683732
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,_QUERCETIN,CHRONIC KIDNEY DISEASE,NCT02848131,Phase 2,0.3779075161962073,0.6220924838037929
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,_SEMAGLUTIDE,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.2910542621607924,0.7089457378392079
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,_SAPACITABINE,BREAST CANCER,NCT03641755,Phase 1|Phase 2,0.8726778603959296,0.12732213960407013
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,_SALSALATE,PCOS,NCT03229408,Phase 2,0.3135517518968991,0.6864482481031016
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,_SALSALATE,PREECLAMPSIA,NCT03482440,Early Phase 1,0.2279341755070057,0.7720658244929947
CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,_CLENBUTEROL,AMYOTROPHIC LATERAL SCLEROSIS,NCT04245709,Phase 2,0.7066989905123058,0.29330100948769405
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,PAIN,NCT04313179,Not Applicable,0.1452452419596076,0.8547547580403925
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,IRON DEFICIENCY ANEMIA TREATMENT,NCT03610230,Not Applicable,0.07119962102656632,0.9288003789734338
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],_IRON_SUCROSE,IRON DEFICIENCY ANEMIA TREATMENT,NCT03610230,Not Applicable,0.16290967323882016,0.8370903267611799
OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_SORBITOL,NON-ALCOHOLIC FATTY LIVER DISEASE,NCT04330326,Phase 2,0.3005632848743509,0.6994367151256491
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,_GENISTEIN,ALZHEIMER DISEASE,NCT01982578,Not Applicable,0.5291004726303301,0.4708995273696698
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,_RESVERATROL,"DIABETES MELLITUS, TYPE 1",NCT03436992,Not Applicable,0.5329148168090536,0.4670851831909464
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,_RESVERATROL,FRIEDREICH ATAXIA,NCT03933163,Phase 2,0.4430024440568869,0.5569975559431132
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,_RESVERATROL,DILATED CARDIOMYOPATHY,NCT01914081,Phase 3,0.5761803873349092,0.4238196126650906
OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_TREHALOSE,ACUTE CORONARY SYNDROME,NCT03700424,Phase 2,0.219312050111332,0.7806879498886681
CCCCCCCC/C=C/CCCCCCCC(=O)O,_OLEIC_ACID,CYSTIC FIBROSIS,NCT04531410,Not Applicable,0.3966211080720876,0.6033788919279125
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,_LINOLEIC_ACID,CYSTIC FIBROSIS,NCT04531410,Not Applicable,0.17029497650366365,0.8297050234963365
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,_HESPERIDIN,NON ALCOHOLIC STEATOHEPATITIS,NCT03734510,Not Applicable,0.13792581535131107,0.8620741846486889
CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1,_PERMETHRIN,MALARIA,NCT04102592,Not Applicable,0.1093661139117202,0.8906338860882799
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,_TIPIFARNIB,NON SMALL CELL LUNG CANCER,NCT03496766,Phase 2,0.5870014514629766,0.41299854853702345
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,_FENRETINIDE,PERIPHERAL T CELL LYMPHOMA,NCT02495415,Phase 2,0.8948153715568191,0.10518462844318092
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,_DEXLANSOPRAZOLE,GASTRO ESOPHAGEAL REFLUX,NCT03202537,Early Phase 1,0.5181868529238031,0.481813147076197
CC[C@@H]1[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@H]3[C@H](C)CCC(=O)O)[C@@H]2[C@@H]1O,_OBETICHOLIC_ACID,OBESITY,NCT02532335,Phase 1,0.1943017361488941,0.8056982638511063
CC[C@@H]1[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@H]3[C@H](C)CCC(=O)O)[C@@H]2[C@@H]1O,_OBETICHOLIC_ACID,NON-ALCOHOLIC FATTY LIVER DISEASE,NCT03836937,Not Applicable,0.1943017361488941,0.8056982638511063
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,_TENALISIB,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",NCT04204057,Phase 2,0.7204189664401852,0.27958103355981445
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,_SELICICLIB,CUSHING DISEASE,NCT03774446,Phase 2,0.7172092679972072,0.2827907320027925
COc1cc(C(=O)c2c(C)oc3c(OP(=O)(O)O)c(OC)ccc23)cc(OC)c1OC,_BNC105,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT03454165,Phase 1,0.7013206361104709,0.2986793638895289
Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,_ENZASTAURIN,DIFFUSE LARGE B-CELL LYMPHOMA,NCT03263026,Phase 3,0.6121869588629424,0.3878130411370575
Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,_ENZASTAURIN_HYDROCHLORIDE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT03263026,Phase 3,0.6026661574397436,0.3973338425602563
[I-].[K+],_POTASSIUM_IODIDE,DENTAL CARIES IN CHILDREN,NCT04001959,Not Applicable,0.16855366068329855,0.8314463393167014
C[N@+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_METHYLNALTREXONE,PANCREATIC CANCER,NCT04083651,Phase 2|Phase 3,0.4686783629272845,0.5313216370727154
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,_HYALURONIC_ACID,GASTRO ESOPHAGEAL REFLUX,NCT04202692,Not Applicable,0.20408023313165444,0.7959197668683458
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,_HYALURONIC_ACID,LUMBAR SPINAL STENOSIS,NCT02459392,Not Applicable,0.12486672743617055,0.8751332725638299
Cc1c(O)c(=O)ccn1C,_DEFERIPRONE,AMYOTROPHIC LATERAL SCLEROSIS,NCT03293069,Phase 2|Phase 3,0.06356242786969342,0.9364375721303068
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,_TESAMORELIN,MILD COGNITIVE IMPAIRMENT,NCT02572323,Phase 2,0.3149166639279267,0.6850833360720735
C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2,_LINACLOTIDE,FUNCTIONAL CONSTIPATION,NCT04110145,Phase 2,0.34668923432941084,0.6533107656705894
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,_FLUTICASONE_FUROATE,PHARMACOKINETICS,NCT03739294,Phase 2,0.19409348806019186,0.8059065119398082
OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,_VILANTEROL,PHARMACOKINETICS,NCT03739294,Phase 2,0.3026744037379791,0.6973255962620211
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,_CANAGLIFLOZIN,HEART FAILURE,NCT04252287,Phase 3,0.35717587217986485,0.6428241278201352
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,_SELEXIPAG,"HYPERTENSION, PULMONARY",NCT04175600,Phase 3,0.4400735777420479,0.5599264222579522
Cc1ncc(CO)c(CN)c1O,_PYRIDOXAMINE,"DIABETES MELLITUS, TYPE 2",NCT03778580,Not Applicable,0.3709903453524423,0.6290096546475575
Cc1ncc(CO)c(CN)c1O,_PYRIDOXAMINE,ABDOMINAL OBESITY METABOLIC SYNDROME,NCT02954588,Not Applicable,0.3043679185190095,0.6956320814809908
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,_BRIVANIB,OVARIAN CANCER,NCT03895788,Phase 1,0.4457074152313571,0.554292584768643
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O,_DOTATATE,NEUROENDOCRINE TUMORS,NCT04318561,Phase 1|Phase 2,0.2382272623297836,0.7617727376702164
C[S@@](=O)CCCCN=C=S,_SULFORAPHANE,DEPRESSION,NCT04246905,Phase 2,0.2894775478933327,0.7105224521066676
C[S@@](=O)CCCCN=C=S,_SULFORAPHANE,ALZHEIMER DISEASE,NCT04213391,Not Applicable,0.2892578573475457,0.7107421426524546
NC(=O)c1nc(F)cnc1O,_FAVIPIRAVIR,CORONAVIRUS INFECTION,NCT04373733,Phase 3,0.4491637609533245,0.5508362390466757
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1,_PIMONIDAZOLE,PROSTATE CANCER,NCT02095249,Not Applicable,0.6706114862830402,0.3293885137169595
O=N[O-],_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.3107311251711414,0.6892688748288588
O=N[O-].[Na+],_SODIUM_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.7755942303125744,0.22440576968742587
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,_RELAMORELIN,GASTROPARESIS|DIABETES MELLITUS,NCT03420781,Phase 3,0.6941886789750381,0.3058113210249616
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,_ETELCALCETIDE,END STAGE RENAL DISEASE,NCT03795558,Phase 2,0.5893490298960538,0.41065097010394624
C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,_SERLOPITANT,EPIDERMOLYSIS BULLOSA,NCT03836001,Phase 2,0.4428011302413138,0.5571988697586863
Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,_NETARSUDIL,"GLAUCOMA, OPEN-ANGLE",NCT04234932,Early Phase 1,0.5635774983747852,0.4364225016252146
Nc1ncc2ncn(CC3(OCP(=O)(O)O)CC3)c2n1,_BESIFOVIR,CHRONIC HEPATITIS B,NCT02792088,Phase 3,0.1418703837156225,0.8581296162843778
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,_IMETELSTAT,MYELODYSPLASTIC SYNDROME,NCT02598661,Phase 2|Phase 3,0.7622431636115423,0.2377568363884573
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,_VOXELOTOR,SICKLE CELL DISEASE,NCT04247594,Phase 2,0.31956239945926823,0.6804376005407319
C[C@@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]2N)[C@H](O)[C@@H]1O,_ELX-02,CYSTIC FIBROSIS,NCT04135495,Phase 2,0.7320551514065307,0.267944848593469
C[C@]1([18F])C[C@@](N)(C(=O)O)C1,_FLUCICLOVINE_F18,GLIOBLASTOMA,NCT03926507,Early Phase 1,0.6352532214843699,0.36474677851563
CN1CC[C@]2(C)c3cc(OC(=O)Nc4ccccc4)ccc3N(C)[C@H]12,_POSIPHEN,ALZHEIMER DISEASE,NCT02925650,Phase 1|Phase 2,0.5340969602085994,0.4659030397914005
CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1,_LB-100,MYELODYSPLASTIC SYNDROME,NCT03886662,Phase 1|Phase 2,0.7620765426306311,0.23792345736936896
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,_AZD7325,FRAGILE X SYNDROME,NCT03140813,Phase 1,0.3710077195606263,0.6289922804393737
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,_SECRETIN,PANCREATIC CANCER,NCT03404661,,0.5612903004657948,0.4387096995342051
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC,_TEDUGLUTIDE,HYPERLIPIDEMIA,NCT03442972,Phase 2|Phase 3,0.4182683536761953,0.5817316463238049
NC(=O)OCC(COC(N)=O)c1ccccc1,_FELBAMATE,EPILEPSY,NCT03196466,,0.4200465857464072,0.579953414253593
O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,_DANTROLENE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.6832663008703643,0.3167336991296353
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,SCHIZOPHRENIA,NCT03817502,Phase 3,0.5867410269011514,0.4132589730988489
N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,_TIPIRACIL,COLORECTAL CANCER,NCT03974594,Phase 1,0.3400708870121528,0.6599291129878473
COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,_ENCORAFENIB,NON SMALL CELL LUNG CANCER,NCT03915951,Phase 2,0.4682980968521852,0.5317019031478148
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,_LASMIDITAN,MIGRAINE DISORDERS,NCT04396574,Phase 3,0.558962002301561,0.44103799769843904
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,BREAST CANCER,NCT03056755,Phase 2,0.5564586584270945,0.4435413415729055
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,MENINGIOMA,NCT03631953,Phase 1,0.4924451737470456,0.5075548262529544
COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1,_LETERMOVIR,CYTOMEGALOVIRUS INFECTION,NCT03728426,Phase 2,0.7530827426491962,0.2469172573508035
COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1,_LETERMOVIR,CYTOMEGALOVIRUS (CMV) INFECTION,NCT03940586,Phase 2,0.6652198539292048,0.3347801460707946
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,METASTATIC BREAST CANCER,NCT03238196,Phase 1,0.6350719950101659,0.3649280049898341
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.6037460306931609,0.39625396930683904
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,_ERAVACYCLINE,BACTERIAL INFECTIONS,NCT03696550,Phase 1,0.41001393655249097,0.5899860634475089
N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,_RIMEGEPANT,TRIGEMINAL NEURALGIA,NCT03941834,Phase 2,0.5014424033763276,0.4985575966236723
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N,_OZANIMOD,CROHN'S DISEASE,NCT03467958,Phase 3,0.526071118904676,0.4739288810953239
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,PROSTATE CANCER,NCT04136353,Phase 3,0.4045941705264448,0.5954058294735554
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,_ENASIDENIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.5135034501492953,0.4864965498507046
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,_ZANUBRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT04460248,Phase 2,0.3873175566913036,0.6126824433086964
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,_ZANUBRUTINIB,WALDENSTRÖM MACROGLOBULINEMIA,NCT04463953,Phase 2,0.4066667180109624,0.5933332819890377
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,CROHN'S DISEASE,NCT03345849,Phase 3,0.6354116855409636,0.3645883144590364
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,SPONDYLOARTHRITIS,NCT04169373,Phase 3,0.6354116855409636,0.3645883144590364
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ULCERATIVE COLITIS,NCT03006068,Phase 3,0.6022388257864697,0.3977611742135304
C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,_UBROGEPANT,MIGRAINE DISORDERS,NCT04492020,Phase 3,0.5813554992094966,0.4186445007905033
